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Abstract 
A total of 60 non-duplicate enterobacterial species isolated from patients in 
the Prince of Wales Hospital in 1996 which were positive for the double disk 
diffusion test, a screening test for the detection of extended-spectrum P-lactamases 
(ESBLs) were studied. Determination of the minimal inhibitory concentrations 
(MICs) of ceftazidime alone and in the presence of clavulanic acid against the 
isolates showed that only 62% gave ceftazidime: ceftazidime + clavulanate MIC 
ratios > 16，an indication ofESBL production. Ninety-five percent of the putative 
ESBL-producers were resistant to 8 mg/L ceftazidime but all became susceptible to 
ceftazidime plus clavulanate. More than 90% (95-97%) of these putative ESBL-
producers were resistant to piperacillin, cefuroxime and aztreonam and 32 - 46% 
were resistant to cefoxitin, ceftriaxone and cefotaxime. A smaller proportion of the 
23 non-ESBL-producers as compared to ESBL-producers were resistant to 
ceftazidime (57%) but more were resistant to the other cephalosporins, piperacillin 
and aztreonam (48% - 100%). Similar proportions of ESBL and non-ESBL-
producers were resistant to the aminoglycosides and quinolones (13 — 41%). 
Multiple resistance was common amongst both groups of organisms (98%). Only 
10 (27%) of the 37 ESBL-producers and two (9%) of the 23 non-ESBL-producers 
could transfer their resistances at frequencies of 10"^ ^ - 10"^ . The kinetics of P-
lactamase from four isolates were studied; one Morganella morganii, one 
Escherichia coli, and two Serratia marcescens since M. morganii and S, marcescens 
are rare hosts of ESBLs and the E. coli isolate exhibited high-level cefuroxime 
resistance (MIC > 1024 rngFL). Substrate profiles of the P-lactamases from M 
ii 
morganii and E. coli indicated that they were probably novel enzymes, p_ 
Lactamases from the two S. marcescens isolates were SHV-5. Amplification of 
DNA using TEM- and SHV-specific primers and oligotyping of all the isolates 
indicated that most (60%) E. coli produced ESBLs ofTEM- or SHV-type while the 
majority of the non-ESBL-producers produced enzymes that were not TEM- or 
SHV-type. All the K. pneumoniae isolates produced ESBLs, most of which (73%) 
were TEM- or SHV-type produced singly or in combination by the isolates. In 
contrast, most Enterohacter sp. (54%) produced SHV-type ESBLs and similar 
proportions ofthose that were non-ESBL-producers produced TEM-, SHV-type and 
non-TEM-non-SHV-type P-lactamases. All seven M. morganii produced P_ 
lactamases that were non-TEM- or non-SHV-type. SHV-type ESBLs appeared to be 
the predominant ESBLs and the majority of organisms producing enzymes were K. 
pneumoniae and Enterobacter sp. 
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Chapter 1 Introduction 
Introduction 
1.1. Beta-Lactam Antibiotics 
Beta-lactam (p—lactam) antibiotics are anti-microbial agents that include natural 
products of microorganisms and synthetic compounds. They possess a p-lactam ring 
and include the classical families penicillins and cephalosporins. Non-classical 
P-lactams such as monocyclics and carbapenems have also been developed. Many 
schemes have been devised to classify p-lactams and these are based on the 
structure, activity spectrum, and the ability to withstand resistance mechanisms. 
1.1,1, Penicillins 
Penicillin was the first of the p-lactam antibiotics discovered in the late 1920's 
by Alexander Fleming (Chain et al., 1940). It was produced by a mould Penicillium 
notatum and inhibited the growth of many microorganisms, notably Gram-positive 
bacteria. Subsequently, semi-synthetic penicillin-like antibiotics with broader 
antibacterial spectrum were developed. 
Penicillins have the 6-aminopenicillanic acid structure. They include benzyl 
penicillin Q3enicillin G), the first penicillin introduced for therapeutic use, 
phenoxymethylpenicillin Q3emcillin V), stable to acidic medium and orally 
absorbed, and dimethoxybenzylpenicillin (methicillin), oxacillin (Doyle et al.) 
1 
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1961), cloxacillin (Knudsen et al, 1962) and flucloxacillin (Sutherland et al, 1970), 
stable to staphylococcal p-lactamases. 
Since penicillin could only inhibit Gram-negative bacteria at high 
concentrations and therefore of no therapeutic significance, derivatives ofpenicillins 
were developed to widen their spectrum of activity. These penicillins belong to four 
chemical groups namely aminopenicillins, acrylureidopenicillins, carboxypenicillins 
and amidinopenicillins. Aminopenicillins include ampicillin which is acid-stable and 
its esters (bacampicillin and talampicillin) and analog (amoxicillin). The esters are 
pro-dmgs that are hydrolyzed by mammalian esterases and release ampicillin during 
absorption. The analog (amoxicillin) can achieve blood levels twice those of 
ampicillin after an oral dose. — 
Substitution of the a-amino group of ampicillin with heterocyclic groups yields 
acrylureidopenicillins. The activities against Gram-negative bacilli were enhanced 
but they must be given parenterally. 
The carboxypenicillins such as carbenicillin and ticarcillin have anti-
pseudomonal activity although the latter has enhanced specific activity (Sutherland 
et aL, 1970). 
The amidinopenicillins such as mecillinam and its oral ester pivmecillinam are 
the only amidinopenicillins available for clinical use. They are active usually against 
rapidly growing fermentative Gram-negative rods. 
2 
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1.1.2, Cephalosporins 
Cephalosporins are compounds that have the 7-aminocephalosporanic acid 
structure; the p—lactam ring is fiised to a six-membered dihydrothiazine ring rather 
than the five-membered thiazolidine ring of penicillins. Cephalosporins have 
different Gram-positive and Gram-negative coverage, and are less prone to cause 
hypersensitivity reactions. Cephalosporins can be classified into four groups or into 
four generations. The four groups are antistaphylococcal, antienterobacterial and 
antipseudomonal cephalosporins and cephamycins; and the four generations are the 
first to fourth generation cephalosporins. 
Antistaphylococcal cephalosporins are mainly active against Gram-positive 
organisms. Although cephalothin was the first cephalosporin to be of climcal use 
widely (Klein et al, 1964), it would be converted to a compound with low 
antibacterial activity by mammalian esterases. Subsequently, cefazolin and 
cephaloridine that are metabolically stable and not susceptible to esterases were 
developed. However, these two cephalosporins only have weak anti-Gram-negative 
activity. 
Of the parenteral cephalosporins, cefamandole and cefuroxime were the first 
p-lactamase-resistant ones to be brought into clinical use. Later, cephalosporins 
with greater p-lactamase-resistant ability such as cefotaxime，ceftriaxone and 
ceftizoxime (Williams & Moosdeen, 1987) were devloped. Cefotaxime has high 
antienterobacterial activity but metabolically unstable (Brogard & Comte, 1982) 
while ceftriaxone and ceftizoxime are metabolically stable. Although most of these 
n 
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antienterobacterial cephalosporins have relatively short half-lives, ceftriaxone has 
prolonged half-life. 
The oral antienterobacterial cephalosporins that were developed in the late 1960s 
and early 1970s, included cephalexin, cephradine and cefaclor. The more recent oral 
cephalosporins included cefuroxime axetil, cefetamet and ceftibuten. 
Since the newer cephalosporins such as cefotaxime and ceftriaxone did not have 
good in vivo activity against pseudomonads, cephalosporins with specific anti-
pseudomonal activity such as cefoperazone, ceftazidime and ce^pirome were 
developed. They also showed good antienterobacterial activity while cefpirome is 
also active against enterococci (Schafer et al, 1992). 
Cefoxitin was the first of the cephamycins to be introduced clinically. It is stable 
to a wide range of p-lactamases, including those of Bacteroides spp. Other 
cephamycins subsequently developed included cefotetan, cefmetazole and 
moxalactam. Cefoxitin and cefmetazole are active against many Gram-negative 
aerobes while the anti-bacterial spectrum of cefotetan and moxalactam are similar to 
that of cefotaxime (Williams, 1983; Jones, 1983). 
The cephalosporins can also be classified into generations, with the first 
generation cephalosporins being initially developed and most active against Gram-
positives. Examples include cephalexin and cephradine. Since they have no useful 
activity against Gram-negatives, cephalosporins with higher anti-Gram-negative 
activity subsequently developed are classified as second and third generation 
cephalosporins, the later generation having the highest anti-Gram-negative activity 
4 
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but compromised by lowest anti-Gram-positive activity. Examples of second 
generation cephalosporins include cefuroxime and cefamandole and examples of 
third generation cephalosporins included cefotaxime and ceftazidime. The fourth 
generation cephalosporins such as ceJ^pirome and cefepime are the most recently 
developed cephalosporins especially designed to counteract the chromosomal p-
lactamases, 
1.1,3. Non-Classical Beta-Lactams 
There are four main groups of non-classical p-lactams, namely monocyclic 
p-lactams, carbapenems, clavams and penicillanic acid sulfones. 
Monocyclic p-lactams (monobactams) have a single-p-lactam ring structure. 
The only monobactam of clinical significance is aztreonam (Sykes et al., 1981; 
Sykes & Bonner, 1985), which is used to treat Gram-negative infections and has no 
useful Gram-positive activity. Carbapenems resemble penicillins and are based on 
thienamycin, which has wide antibacterial spectrum but chemically unstable (Kahan 
et al, 1979). Stable derivatives have been developed and these include imipenem 
(Edwards et al, 1989) and meropenem (Kropp et al, 1980). Clavams (clavulanic 
acid) (Cole, 1979) and the penicillanic acid sulfones sulbactam and tazobactam are 
the two major groups of clinically important p-lactamase inhibitors. 
5 
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11-4. Mode OfAction Of Beta-Lactams 
1.1.4.1. Penicillin Binding Proteins {PBPs) 
P-Lactams exert their antibacterial effect by binding covalently to the cell-wall 
biosynthetic enzymes situated at the cell wall-cell membrane interface. These 
biosynthetic enzymes, commonly known as penicillin binding proteins (PBPs) 
(Spratt, 1977), catalyze polymerization of the peptidoglycan network that is an 
important component of the bacterial cell wall. The PBP adds each newly formed 
cell wall building unit, which consists of a disaccharide-pentapeptide to the free 
sugar at the end of a peptidoglycan chain and cross-links the peptidoglycan chains 
by connecting their pentapeptide side chains. The cross-linking reaction connects the 
thousands of peptidoglycan chains in the bacterial cell wall into an extremely strong, 
chemically resistant mesh. 
1.1.4.2. Inhibition Of Cell Wall Biosynthesis 
P—Lactams inhibit cell wall biosynthesis by imitating the molecular structure of 
the terminal D-alanyl-D-alanine portion of an uncross-linked pentapeptide side 
chain, which is the natural substrate of the transpeptidase. The transpeptidase 
hydrolyses the peptide bond between the two D-alanine residues and covalently 
bonds to the penultimate residue, releasing the other. The penultimate D-alanine is 
then transferred from the enzyme to the basic amino acid of a side chain, giving rise 
to a cross-link and restoring the active site of the enzyme. When a p-lactam 
interacts with transpeptidase, the p-lactam is hydrolyzed and covalently bonds with 
the transpeptidase. Unlike the penultimate D-alanine, the covalently-bound 
6 
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P-lactam cannot be transferred to the neighboring side chain and remains bound to 
the active site of the enzyme, which is then inhibited. The alteration of the 
transpeptidase activities hinders the cross-linking of the bacterial cell wall, therefore 
lessens the integrity of the cell wall and causes cell lysis. 
1.2. Resistance Mechanisms 
Although p-lactam antibiotics act on precise biochemical targets and exert lethal 
effects on bacteria, many bacteria have developed various means to evade from the 
effects of p-lactams. These include modifications of normal PBPs, production of 
P—lactamases，cellular exclusion and target site bypass. 
1.2.1. Modifications Of Normal PBPs 
Bacteria that are resistant to p-lactam antibiotics possess modified PBPs. Most 
of the modifications lower the affinity of the PBPs for p-lactam but not the normal 
substrates (Spratt, 1994). Such PBPs modifications are usually due to base mutations 
in the genes coding for PBP, which in tum lead to the change of amino acid residues 
within the active site. The alteration is usually accompanied by another mutation so 
as to stabilize the altered protein. Thus the formation of a modified PBP in the 
p-lactam-resistant strain is the consequence of sequential mutation and natural 
selection. 
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1.2.2. Production Of Beta-Lactamases 
3-Lactam antibiotics can be inactivated by enzymatic hydrolysis of the 
P-lactam ring. p-Lactamase is an enzyme that plays a major role in the hydrolytic 
cleavage of the p-lactam ring at its amide bond and thus inactivating the p—lactams. 
Most p-lactamases function by serine ester mechanism (Fisher et al, 1980) but a 
few are zinc-dependent (Spratt, 1994). 
1.2.3. Cellular Exclusion 
Porins are proteins present in the outer membrane that assemble to form pores. 
They allow the passive transport of hydrophilic substances and provide an entrance 
for most p—lactams to access to the cell wall-cell membrane interface. In some 
P-lactam-resistant bacteria, the number or the diameters of such pores are reduced, 
thereby reducing the number of p-lactam molecules into the bacterial cell. 
1.2.4. Target Site Bypass 
Target site bypass is common in staphylococci. The newly synthesized essential 
PBP has low affinity to methicillin and other anti-staphyiococcal penicillins. 
Several features are important for p-lactam antibiotics to be effective in its 
activity against bacteria. Firstly, the ability to penetrate through the outer layers of 
the bacterial cell to reach the targets on the surface of the bacterial inner or 
cytoplasmic membrane. Secondly, the p—lactams should be able to bind to the 
appropriate targets at low concentration and inhibit peptidoglycan synthesis. Thirdly, 
they should be able to avoid destruction by p-lactamases. 
8 
Chapter 1 Introduction 
1.3. Beta-Lactamases 
1.3,1. Discovery Of Beta-Lactamases 
3-Lactamases had existed in parallel to the discovery of penicillin and were 
widely distributed in normal bacteria. The first p-lactamase was reported at the 
same time when penicillin was introduced in clinical use in man (Abraham & Chain, 
1940). p-Lactamase was thought to be an endopeptidase, which erodes the bacterial 
cell wall from the inside of the cell. 
The discovery of p-lactamases can be traced back to the observation by 
Fleming in 1929 that some groups of bacteria were resistant to penicillin. This 
resistance was explained to be due to a penicillinase that inhibited the antimicrobial 
activity of penicillin. 
The clinical importance of this enzyme first became apparent in the 1950's, 
when p-lactamase-producing strains of Staphylococcus aureus appeared and made 
penicillin totally ineffective in the treatment of staphylococcal infection (Kirby, 
1945). In less than a decade after the introduction of penicillin for clinical use, it was 
noted that 73% of S. aureus isolates from patients in a Boston hospital were 
penicillin-resistant (Finland, 1971). At present more that 90% of S. aureus 
worldwide are resistant to penicillin (Lacey, 1984) and resistance of Gram-negative 
bacilli to P-lactams including third-generation cephalosporins and other newly 
developed p-lactams is a major clinical problem in many parts of the world. 
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1,3.2. Classification Schemes OfBeta-Lactamases 
Many schemes have been devised to classify p-lactamases. These schemes 
were based either on the phenotypic properties or the molecular structure of the 
enzymes. 
The earliest classification scheme could be traced back to 1968 when anti-
3-lactamase antisera were used to compare different enzymes (Sawai et al, 1968). 
Later in 1973，Richmond and Sykes proposed grouping the enzymes into five 
categories based on their substrate profiles (Richmond and Sykes, 1973). This 
scheme was further expanded in 1976 when isoelectric point was added as an 
additional criterion to differentiate plasmid-mediated p-lactamases and a three-
letter, one-number notation was given (Sykes and Matthew, 1976; Matthew, 1979). 
Plasmid-mediated p-lactamases were grouped according to whether they were most 
active against benzylpenicillin, oxacillin or carbenicillin (Medeiros, 1984). 
However, problems such as very dissimilar enzymes were grouped together had 
prompted Bush (Bush, 1989a, b & c) to make a new scheme which was 
subsequently revised (Bush et al, 1995). In this most recent scheme (Bush et al., 
1995), four different fimctional groups are designated: group one are 
cephaloporinases (molecular class C) that are not well inhibited by clavulanic acid, 
group two p-lactamases (molecular class A or D) are generally inhibited by 
P-lactamase inhibitors, group three are metallo-p-lactamases (molecular class B) 
that are poorly inhibited by all classical p-lactamase inhibitors except EDTA and p-
chloromemribenzoate (pCMB) and group four are penicillinases (of unknown 
molecular class) that are not inhibited by clavulanic acid. 
10 
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In molecular classification, four classes of p-lactamases are defined, namely A 
to D (Joris et aL, 1991). p-Lactamases are classified in terms of sequences as 
proposed by Ambler and colleagues (Ambler, 1980), and revised by Jaurin et al. in 
1981 and Mossakowska et al. in 1989. This sequence-based classification would not 
be distorted by mutations. 
1.3,3. Chromosomally-Mediated J3-Lactamases 
Genes coding for the production of p-lactamases can be located on the 
chromosome or plasmid. Chromosomally-mediated enzymes inactivate p-lactams 
by binding covalently to the drug to form an inert complex. Almost all Gram-
negative bacteria produce some chromosomal p-lactamases (Matthew & Harris, 
1976). The amount of enzyme produced is usually very low so that the isolates are 
frequently p-lactam-sensitive. However, the production can be increased due to 
induction or changes to the number of p-lactamase genes or their regulation 
fNormark et al., 1977; Jaurin et al., 1981). 
There are two major groups of chromosomal p-lactamases: "typical 
cephalosporinases" which preferentially hydrolyse the cephalosporins and 
"cephalosporinases with broad substrate specificity" which can also hydrolyse some 
of the penicillins (Sawai et aL, 1982). The ‘‘typical cephalsporinases" are produced 
constitutively by bacteria such as E. coli, Citrobacter freundii, or inducibly by 
Enterobacter sp., P. aeroginosa, etc. Examples of the second group of enzymes 
include the inducible p-lactamases produced by Proteus vulgaris and K. 
pneumoniae. 
11 
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1.3,4, Plasmid-Mediated fi~Lactamases 
Most of the clinically-important plasmid-mediated p-lactamases are produced 
by Gram-negative bacteria while those produced by S. aureus are the only important 
ones found amongst Gram-positive bacteria (Bauemfeind, 1986). 
Horizontal transfer of resistant genes was mediated not only by plasmid but also 
by transposons. Transposons are mobile DNA elements (< 2 kb) that harbor genes 
such as antimicrobial resistance determinants and are capable of transfer amongst 
plasmids and chromosomes (Galas & Chandler, 1989). Many transposons have been 
described in both Gram-positive and Gram-negative bacteria (Bennett, 1999). They 
are usually designated as Tn. 
A number of P-lactamases are encoded by transposons. These include TEM-1 
by Tni (Heffron et aL, 1981); TEM-2 by Tn； (Rubens et al” 1976); SHV-1 by a 15 
kb transposon unrelated to Tn7 (Nugent & Hedges, 1979); and OXA-1 by Tn2603 
(Yamamoto et aL, 1981). Some ESBLs are also encoded by transposons e.g. TEM-
12 (Heritage et al., 1992), TEM-52 (Poyart et al., 1998), OXA-16 (Danel et al” 
1998). By being bome on transposons, the spread of p_lactamase genes amongst 
bacterial strains of different species is greatly facilitated (Mabilat et aL, 1992). 
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1.3.4.1. Beta-Lactamases Of Gram-Positive Bacteria 
P-Lactamases of S. aureus are mainly penicillinases. The genes coding for the 
production of these enzymes have spread to coagulase-negative staphylococci and 
even to Enterococcus faecalis (Murray & Mederski-Samaroj, 1983). 
Characterization of staphylococcal p-lactamases is difficult since they are not 
readily distinguishable by markers frequently used for classifying p-lactamases such 
as substrate profiles and susceptibility to p-lactamase inhibitors. Despite these 
difficulties, studies of staphylococcal p-lactamases have been attempted with some 
success (Zygmunt et al, 1992). 
1.3.4.2. Beta-Lactamases Of Gram-Negative Bacteria 
The wide variety of p-lactamases produced by Gram-negative bacteria was 
probably due to the extensive use of penicillins and cephalosporins (Moellering, 
1991). More than 140 plasmid-mediated p-lactamases had been described and the 
number is increasing as more new enzymes are discovered. Most of them fall into 
Group two ofBush's functional scheme (Bush et al, 1995). 
TEM-1 is the commonest type of p-lactamases of Gram-negative bacteria. It 
was the first discovered in an ampicillin-resistant E. coli isolate in 1965 (Datta & 
Kontomichalou, 1965). Subsequently, this enzyme was found in different bacterial 
genus, including Pseudomonas, Vibrio, Haemophilus and Neiserria (Stewart, 1974; 
Matthew, 1979; Sanders & Sanders, 1992). 
TEM-2 and SHV-1 are two other plasmid-mediated P-lactamases commonly 
found in Gram-negative bacteria. TEM-2 differs from TEM-1 by only one amino 
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acid while SHV-1 is universally found as a chromosomal enzyme in K. pneumoniae. 
However, SHV-1 has also been reported in E. coli (Pitton, 1972; Roupas & Pitton, 
1974). It has been suggested that the SHV-1 gene on the chromosome of Klebsiella 
later became incorporated into a plasmid P^ugent & Hedges, 1979). These enzymes 
hydrolyze mainly ampicillin and the carboxypenicillins but not the aminothiazolyl 
cephalosporins, monobactams and carbapenems. They can be effectively inhibited 
by clavulanate and sulbactam. 
Other plasmid-mediated p-lactamases include the oxacillin-hydrolyzing 
enzymes (OXA-type) produced by various enterobacterial species and R 
aeruginosa, carbenicillin-hydrolyzing enzymes (CARB- and PSE-type) mainly 
produced by P. aeruginosa and the recently described ones such as MIR-1 and 
MOX-1 etc. (Bush et al, 1995). 
1.3.4.3. Extended-Spectrum p—Lactamases (ESBLs) 
1.3.4.3.1. Overview OfESBLs 
Extended-spectrum p-lactamases (ESBLs) are enzymes that are capable of 
hydrolyzing to varying degrees various P-lactams including oxyiminocephaloporins 
and aztreonam. Bacterial organisms producing these enzymes become clinically 
resistant to these antibiotics, thereby creating serious therapeutic problems. Besides, 
genes coding for ESBLs are usually located on plasmids which facilitate their spread 
amongst many species. K. pneumoniae and E. coli are the most common hosts of 
ESBLs (Jacoby & Medeiros，1991; Bush, 1996). However, other organisms which 
are infrequent producers of ESBLs such as Enterohacter cloacae, C. freundii and R 
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aeruginosa (^ordmann et al, 1993; Mugnier et al” 1996; Danel et aL, 1999) have 
increasingly been found to produce a variety ofESBLs. 
ESBL was first detected in Klebsiella sp. isolated in Germany in 1983 that were 
resistant to the broad-spectrum cephalosporins (Knothe et al., 1983). The resistance 
was due to a p-lactamase related to SHV-1 and the encoding gene was bome on a 
transferable plasmid (Kliebe et aL, 1985). Subsequently, Klebsiella sp. resistant to a 
similar range of cephalosporins were isolated in France (Brun-Buisson et al” 1987). 
However, the p-lactamase conferring the resistances was related to TEM-1 (Sirot et 
al., 1987). Within a few years, different enzymes related to SHV- or TEM-type 
p-lactamases have evolved in isolates from many parts of the world (Philippon et 
a/.,1989;Payne&Amyes,1991;Livermore&Williams,1996). 
The most prevalent types ofESBLs are members of the TEM and SHV families. 
They are mutants of the classical TEM-1, TEM-2 and SHV-1 enzymes and have up 
to 15 heterogeneous amino acid positions in the protein sequences of the enzymes 
(Knox, 1995). Some of the mutations are critical in expanding the substrate profiles 
or hydrolytic activities of the enzymes while others are silent mutations and have no 
effect on p-lactamase activity. Together they provide information on the origin and 
evolution of the ESBLs. Recently, OXA-type ESBLs have also appeared. 
ESBLs are often given a TEM, SHV or 0XA designation according to the 
enzyme from which they mutated. However, they are sometimes given a second 
name to describe a particular resistance phenotype, e.g. ceftazidimases (CAZ) for 
those which preferentially hydrolyze ceftazidime，cefotaximases (CTX) for those 
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which rapidly hydrolyse cefotaxime (Bauemfeind et al., 1990) and cephamycinase 
(CMY) for those frequently hydrolyzing the cephamycins (Wu et aL, 1999). 
Although ESBLs differ in their hydrolytic activities on the cephalosporins, they may 
have the same pI values e.g. TEM-5 and TEM-11 both have a pI value of 5.6, and 
SHV-1, SHV-2, SHV-2a, SHV-6 and SHV-7 all have a pI value of 7.6. Thus, it is 
not sufficient to solely rely on the pI value of a particular enzyme for identification. 
Instead, kinetic studies of the enzyme, detection of the gene coding for the enzyme 
and sometimes nucleotide sequencing of the gene have to be carried out in order to 
characterize fully the enzyme concerned. 
1.3.4.3.2. Detection 
ESBL producers are often resistant to ceftazidime, cefotaxime or aztreonam but 
some may only have reduced susceptibility to these drugs and can be missed by the 
disk diffusion test. Several methods have been used to screen for the presence of 
ESBL production. These include the double-disk synergy test (Jarlier et. al, 1988), 
three-dimensional test (Thomson & Sanders, 1992) and the E-test (Katsanis et. al., 
1994; Brown etal., 1995). 
The double-disk synergy test (Jarlier et. al, 1988) was claimed to be a specific 
test for detection of strains producing ESBLs and has been used by many workers 
for this purpose (Sirot el al, 1992; Goldstein et. al., 1993; Naas et. al, 1999). In this 
test, cefotaxime, ceftazidime and aztreonam disks are placed 30 mm away from an 
amoxicillin/clavulanate disk at the center. An extension of the edge of the 
cefotaxime, ceftazidime or aztreonam inhibition zone towards the 
amoxicillin/cla\ailanate disk indicates synergy. However, if there is only slight 
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synergy between the ceftazidime and clavulanate disks, the disks should be put one 
or two cm apart (Thomson & Sanders，1992; Naas et. al, 1999). 
The three-dimensional test (Thomson & Sanders, 1992) is similar to the disk 
diffusion test QS[ational Committee for Clinical Laboratory Standards fNfCCLS), 
1993b) except that a circular slit containing a standard bacterial inoculum is made in 
the agar three mm from the antibiotic disks towards the interior of the plate. This test 
can be used to determine antibiotic susceptibility as well as substrate profile of the 
p-lactamase produced by the strain to be tested. A distortion of the zone of inhibition 
towards the slit would indicate inactivation of the antibiotic contained in the disk by 
P-lactamase. Despite of its advantage in being able to provide information on the 
antibiotic susceptibility and p-lactamase production, this test requires strict 
adherence to the procedures recommended by the NCCLS (1993b) in terms of the 
size of both inocula (the inoculum for the surface of the plate and that for the 
circular slit) and the moisture content of the agar. If the agar is too dry, the slit will 
widen during incubation and results would be unreliable. 
The Etest ESBL strip is a strip with ceftazidime gradient at one end and 
ceftazidime with clavulanate at the other (Brown et al., 1995). After inoculation of 
an agar plate with a bacterial suspension, the strips are applied to the plate and 
incubated. The MIC of ceftazidime and ceftazidime + clavulanate is indicated at the 
point of inhibition of growth and the ratio of ceftazidime: ceftazidime + clavulanate 
is then calculated. A ratio of > 16 is taken as indication of presence of ESBL. 
Although this test was reliable for the detection of ESBL, those that did not confer 
17 
Chapter 1 Introduction 
resistance to ceftazidime and not markedly inhibited by clavulanate would be missed 
(Brown et aI., 1995). 
1.3.4.3.3. TEM-Type ESBLs 
At the time of writing, TEM-type p-lactamases have been named up to TEM-
60, and more than 30 of these are ESBLs. These TEM-type enzymes include the 
classical TEM-1 and TEM-2, the ESBLs which hydrolyze the 
oxyiminocephaloporins and aztreonam to various extents such as TEM-3 which is 
also known as CTX-1 since it is a cefotaximase and TEM-24 also known as CAZ-6 
since it is a ceftazidimase, and the broad-spectrum p-lactamases which are not 
inhibited by the p-lactamase inhibitors clavulanic acid and sulbactam, such as 
TEM-30-TEM-39. 
In contrast to the first ESBL that was discovered, TEM-4 was identified in E. 
coli instead of K. pneumoniae. This enzyme was similar to TEM-3 (or CTX-1) in 
resistance phenotype (resistance to cefotaxime, ceftriaxone, ceftazidime and 
I 
aztreonam) and hydrolytic activity (efficiently hydrolyzed cefotaxime and 
ceftriaxone and moderately hydrolyzed ceftazidime) but differed by its pI value Q)I 
=5.9) (Paul^r aL, 1989). 
TEM-E2 was an ESBL produced by a strain of K. oxytoca isolated in 1982. It 
was not characterized until 1990 and thus was claimed to be the first example of a 
TEM-like enzyme conferring transferable resistance to ceftazidime (Payne et aL, 
1990). This enzyme, with a pI of 5.3, hydrolyzed ampicillin, carbenicillin and 
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cephaloridine at rates similar to those of TEM-1 but it also hydrolyzed cefotaxime 
although it did not confer resistance to cefotaxime. 
TEM-5 was thought to be the first of the ceftazidimases to be isolated and was 
therefore designated CAZ-1 when it was characterized (Petit et aL, 1988). This 
enzyme, constitutively produced by K. pneumoniae strains, had a pI of 5.55. These 
strains were more resistant to ceftazidime (MIC = 32 — 64 mg/L) than to cefotaxime 
(MIC 4 - 8 mg/L) and aztreonam (MIC = 4 - 8 mg/L) but were susceptible to 
moxalactam (MIC 二 1 - 2 mg/L) and imipenem (MIC = 0.12 mg/L). Clavulanic acid 
reduced the MICs of ceftazidime to clinically susceptible levels (0.12 - 1 mg/L). 
Hydrolytic activity was highest for ceftazidime (Vmax = 490 vs. Vmax 二 100 for 
penicillin) and cephalothin (Vmax = 380) but was lower for cefotaxime (Vmax = 
150). There was homology between TEM-1 and plasmid DNA of the strains 
producing the enzyme and one or more mutations in TEM genes resulting in the 
production of this p-lactamase was suggested (Petit et al., 1988). Since its substrate 
profile and isoelectric point differed from those of the other known plasmid-
mediated p—lactamases, it was then regarded as a novel enzyme. 
The second of the ceftazidimases to be reported was TEM-8 (CAZ-2) which 
was produced by K. pneumoniae strains that were more resistant to ceftazidime than 
other cephalosporins (Chanal et al., 1988). This enzyme differed from TEM-5 
(CAZ-1) by its isoelectric point (pI 6.0). 
Chanal and colleagues (1989) subsequently discovered three more 
ceftazidimases: TEM-12 (CAZ-3) (pI 5.3)，TEM-24 (CAZ-6) (pl 6.5) and TEM-16 
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(CAZ-7) (pI 6.3) from K. pneumoniae. These isolates were highly resistant to 
ceftazidime (MIC = 32 - 512 mg/L) but remained susceptible to cefotaxime (MIC = 
0.5 - 8 mgy^). Although these enzymes hydrolyzed ceftazidime preferentially and 
cefotaxime sparingly, the hydrolytic activities were quite different. CAZ-6 had the 
highest activity against ceftazidime fVmax = 848 vs. Vmax = 100 for penicillin) and 
about four-fold lower activity against cefotaxime (Vmax = 208) while both CAZ-3 
and CAZ-7 had comparatively low hydrolytic activity against ceftazidime (Vmax 二 
10 and 98, respectively) and cefotaxime O^max = 18 and 10, respectively). 
TEM-10 had an isoelectric point of 5.57 and readily hydrolyzed ceftazidime and 
piperacillin while aztreonam was hydrolyzed more slowly (Quinn, et al., 1989). 
Hydrolysis of cefotaxime and ceftriaxone were 42 times slower than ceftazidime. 
A ceftazidime-hydrolyzing ESBL produced by a clinical E coli isolate is TEM-
12. It conferred ceftazidime resistance to its host and had a pI of 5.25 (Weber et al‘, 
1990). In contrast to most other ESBLs, it was chromosomally mediated and its 
hydrolytic activity was so low that it required the presence of outer membrane 
protein (OMP) alterations in order to mediate resistance to ceftazidime. 
TEM-26 had a hydrolytic pattem similar to that of TEM-9 and TEM-10 in that 
ceftazidime and aztreonam was hydrolyzed faster than cefotaxime O^aumovski et 
aL, 1992). DNA sequencing performed on various ESBL^ncoding genes showed 
that a mutation at nucleotide number 512 and 692 leading to amino acid substitution 
ofLYS104 and SER164，respectively was responsible for the ability of the enzyme 
to cleave ceftazidime (Sowek et al., 1991). 
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TEM-28 was also initially isolated from E. coli and the hydrolytic activities 
were similar to those of TEM-6 and TEM-10 in that hydrolysis of ceftazidime was 
faster than that of aztreonam or cefotaxime (Bradford et aL, 1996). The Km values, 
however, were similar for the three enzymes. The predicted amino acid sequence for 
TEM-28 was different from that of TEM-10 and TEM-27 by only one amino acid 
and from that ofTEM-6 by two. 
A novel ESBL, designated as TEM-46 or CAZ-9, was produced by an E. coli 
isolate that was highly resistant to ceftazidime (MIC = 32 mg/L) and aztreonam 
(MIC = 256 mgyOL) but was susceptible to cefotaxime (MIC = 0.5 mg/L) and 
cephalothin 0VQC 二 8 mg/L) (Chanal-Claris et al., 1997). This enzyme had a pI of 
6.5 and showed three amino acid substitutions as compared with the TEM-2 
sequence. 
Gniadkowski and co-workers (1998a) identified three novel TEM-type ESBLs 
from a group of ceftazidime-resistant enterobacterial isolates in 1995 in Poland: both 
TEM-47 and TEM-48 were produced by K. pneumoniae and TEM-49 was produced 
by E. coli. All three enzymes had a pI of 6.0 but they exhibited three and four amino 
acid substitutions as compared to the TEM-1 enzyme. However, they shared three 
amino acid substitutions: SER238, LYS240 and MET265. It was postulated that 
TEM-47 and TEM-49 originated from TEM-48 by various genetic mutations 
(Gniadknowski et al., 1998a). 
Morganella morganii is a rare host for ESBL (Bush et al., 1995; Sirot, 1995; 
Bush & Jacoby, 1997) and the first ESBL from this organism to be characterized 
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molecularly was reported recently (Tessier et aL, 1998). This enzyme, a TEM-21, 
was identified from a M. morganii strain because of its reduced susceptibility to 
expanded-spectrum cephalosporins and aztreonam. Analysis of the nucleotide 
sequence showed that it differed from the TEM-1 sequence by four substitutions 
leading to four amino acid substitutions and four silent mutations. 
Providencia stuartii isolates are usually susceptible to the extended-spectrum 
p-lactams. However, a p-lactamase-producing R stuartii that was resistant to 
ceftazidime and aztreonam was isolated in Italy (Comaglia et al., 1995). 
Susceptibility to penicillins was restored by tazobactam but not by clavulanic acid or 
sulbactam. Characterization of the enzyme showed that it had a high affinity for 
ceftazidime and aztreonam as well as high hydrolytic activity against these two 
cephalosporins and clavulanic acid (Franceschini et aL, 1998). It had four amino 
acid substitutions as compared to the sequence of TEM-1 and was therefore 
designated TEM-60. 
TEM-type ESBLs were usually described in enterobacteria and had rarely been 
reported in P. aeruginosa. This is probably because P. aeruginosa was able to 
derepress the production of chromosomal cephalosporins (Livermore & Yang, 
1987), thereby obviating the need to acquire an ESBL-encoding gene. 
The first TEM-type ESBL isolated from P. aeruginosa is TEM-42. This enzyme 
had high hydrolytic activity against cefotaxime and low hydrolytic activity against 
ceftazidime and aztreonam although it confers resistance to these antibiotics 
(Mugnier et aL, 1996). The blajEu^i gene had four novel nucleotide substitutions 
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leading to four changes in the amino acid sequence: VAL42, SER238, LYS240 and 
MET265. SER238 resulted only in a small increase in the MICs of ceftazidime and 
cefotaxime but LYS240 caused a four- to 16-fold increase in the MIC of ceftazidime 
O^enkatachalam et al., 1994; Blazquez et al., 1995). The presence of both SER238 
and LYS240 would lead to high-level resistance to ceftazidime and cefotaxime 
(Venkatachalam et al, 1994). 
Some ESBLs are responsible only for decreased susceptibility to ceftazidime 
and aztreonam and TEM-7 is one of these. This enzyme was found in a C. freundii 
isolate that exhibited low-level resistance to ceftazidime (MIC = 32 mg/L) and 
reduced susceptibility to aztreonam (MIC = 2 mg/L) (Gutmarm et al” 1988). The 
substrate profile of the enzyme was similar to those o fTEM-l and TEM-2 for the 
penicillins and first-generation cephalosporins (cephaloridine and cephalothin) but 
the rate of hydrolysis of ceftazidime and cefotaxime was increased fVmax = 1.7 and 
1.9, respectively as compared to < 1 for TEM-1 and TEM-2, vs. 100 for penicillin). 
Clavulanic acid restored the susceptibility of the isolate to various p-lactams. 
Although the rate and efficiency of hydrolysis fVmaxy'Km) were low but similar for 
ceftazidime and cefotaxime, the isolate showed resistance to ceftazidime but not to 
cefotaxime, thus other factors such as rates of diffusion across the outer membrane 
(Yoshimura & Nikaido，1985) and affinities for certain penicillin-binding proteins 
(Gutmann et al, 1986) might be responsible. 
Transferable resistance to cefotaxime was first described by Knothe and 
colleagues in K. pneumoniae in 1983 (Knothe et al., 1983) but the enzyme 
responsible for the resistance was not biochemically characterized. Sirot and 
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colleagues (1987) described an enzyme conferring a similar resistance phenotype to 
its K. pneumoniae host. Because of its high hydrolytic activity against cefotaxime 
(Vmax = 445 v .^ Vmax = 100 for penicillin and Vmax 二 178 for ceftriaxone), the 
enzyme was named CTX-1, a cefotaximase but was subsequently renamed TEM-3. 
This enzyme has a pI of 6.3 and the encoding gene was bome on a transferable 
plasmid, pCF04, of95 kb. 
Another group of ESBLs conferred high-level resistance to aztreonam but not 
the other cephalosporins. TEM-22 was the first of such enzymes to be described 
(Arlet et al, 1993). It was detected in a K. pneumoniae isolate that was more 
resistant to aztreonam than to cefotaxime and ceftazidime. It had a pI of 6.3 and 
readily hydrolyzed penicillin, cefotaxime and ceftazidime as did most other ESBLs. 
Although hydrolysis rate for aztreonam was low, it (relative to cephaloridine) was 
nine-fold higher compared with that for TEM-3. The peculiar resistance phenotype 
was probably due to a strong affinity of the enzyme for aztreonam. 
Recently, an ESBL associated with reduced susceptibility to moxalactam in 
addition to resistance to ceftazidime, cefotaxime and aztreonam was detected in K. 
pneumonia isolate in France (Poyart et aL, 1998). The MIC of moxalactam was 
decreased by clavulanic acid. This abnormal resistance phenotype suggested a novel 
ESBL, which was then designated TEM-52. The hydrolytic activities of TEM-52 
were similar to those of TEM-3 but the affinity of TEM-52 for moxalactam was 10-
fold higher than that of TEM-3, thereby explaining the differences in the reduced 
susceptibility to moxalactam of the strain producing TEM-52. The three amino acid 
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substitutions LYS104, THR182 and SER238 present in TEM-52 were responsible 
for the hydrolysis of moxalactam. 
RHH-1 (now also known as TEM-9) was first reported in 1987 (Spencer et al, 
1987) from a K. pneumoniae isolate that was resistant to cefoperazone, ceftazidime 
and aztreonam but sensitive to the older cephalosporins such as cefuroxime and 
cephalexin. It was able to hydrolyze cefotaxime, ceftriaxone, cefoperazone, 
ceftazidime and aztreonam though not at a high rate (Vmax = 16-38 vs. Vmax 二 100 
for cephaloridine) but not cefuroxime, cephalexin and cefoxitin CVmax = < 1 - 6). 
Because of its abnormal substrate profile and pI (5.5), it was then regarded as a new 
enzyme. 
1.3.4.3.4. SHV-Type ESBLs 
Only eight SHV-type ESBLs have so far been identified. These enzymes were 
isolated from a variety of hosts, including K. pneumoniae, K. ozanae, E. coli and P. 
aeruginosa. SHV-2 was the first of the SHV-type ESBL to be described. It had the 
same pI of 7.6 as SHV-1 and was produced by a cefotaxime-resistant strain of K. 
ozanae (Kliebe et al., 1985). The cefotaxime-hydrolyzing property of this enzyme 
was probably a result of a few mutations of the SHV-1 encoding gene. 
There are also a few other ceftazidime-hydrolyzing ESBLs that are of SHV-
type. SHV-5, also known as CAZ-4, was produced by a K. pneumoniae isolate 
(Gutmann et. al, 1989). It caused higher resistance to ceftazidime than SHV-2 did 
due to its higher rate of hydrolysis and high affinity. SHV-4, also known as CAZ-5, 
was similar to SHV-5 in the resistance conferred (ceftazidime- and aztreonam-
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resistance) but differed in pI (Labia et, al, 1989; Gutmarm et. al, 1989). SHV-6 
differed from both SHV-4 and SHV-5 in pI (jpl = 7.6) and resistance phenotype 
(ceftazidime-resistance only) (Arlet et, al, 1991). Hydrolysis rates for penicillins 
and cephaloridine of SHV-6 were also lower than those of SHV-4 and SHV-5. 
However, hydrolysis rates for penicillins and cephaloridine of SHV-6 were similar 
to those of SHV-1 and TEM-1 including hydrolysis of ceftazidime that was 
minimal. It has been suggested that the amino acid substitution at position 162 
(SER162) was solely responsible for the increased spectrum of resistance but 
sparing the hydrolysis of ceftazidime (Collatz et. al, 1984). This substitution was 
probably also present in SHV-6. 
SHV-5 and SHV-9 were functionally similar, with both enzymes conferring 
resistance to ceftazidime and aztreonam, and reduced susceptibility to cefotaxime 
(Prinarakis et. al, 1996). However there were four amino acid differences between 
the two enzymes. SHV-9 lacked GLY-54 due to a deletion of a GGC codon. It had 
ARG140, ASN192 and VAL193 while SHV-5 had ALA140, LYS192 and LEU193. 
The presence ofASN192 and VAL193 also in SHV-1 indicated that SHV-9 had 
evolved from this enzyme. 
In contrast, SHV-7 conferred resistance to ceftazidime and cefotaxime and had 
a pI which was identical to that of SHV-1 and SHV-6 (pI - 7.6) (Bradford et. al, 
1995). This enzyme hydrolyzed cefotaxime much faster than it hydrolyzed 
ceftazidime and it differed from the SHV-1 gene at four nucleotides resulting in four 
amino acid substitutions: PHE8, SER43, SER230 and LYS240. 
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SHV-2a was recently reported from a P. aeruginosa isolate which showed only 
slight synergy between ceftazidime and clavulanate in the double-disk diffusion test 
on routine screening ON^ aas et. al, 1999). The enzyme had a pI 7.6. DNA sequence 
analysis of the encoding gene revealed a point mutation from blasm-2 resulting in a 
LEU35 substitution of the protein. This mutation increased the resistance of the host 
strain to ceftazidime but reduced the resistance to all other cephalosporins ^Sfuesch-
Inderbinen et al, 1995). 
1.3.4.3.5. OXA-Type ESBLs 
ESBLs arising from mutations of classical OXA-type p-lactamases have been 
detected mostly in P. aeruginosa. Although all of them conferred resistance to 
broad-spectrum cephalosporins to their hosts, not all could be inhibited by 
clavulanic acid e.g. OXA-11 (Hall et al., 1993), OXA-15 (Danel etaL, 1997), OXA-
16 (Danel et aL, 1998) and OXA-19 (Mugnier et al., 1998) and might not be 
classified as ESBLs in the strictest sense. However, because of their resistance 
phenotypes, the characteristics of these enzymes will also be reviewed here. 
OXA-11 is an extended-spectrum variant of OXA-10 identified in a P. 
aeruginosa isolate and the first of an extended-spectrum class D p-lactamase (Hall 
et al” 1993). Although this enzyme did not efficiently hydrolyze ceftazidime, it had 
a high affinity for this cephalosporin, causing the strain to become resistant. It 
differed from OXA-10 by two amino acid residues, thereby enabling it to become 
resistant to an expanded range of P-lactams. It had a pI of 6.4. 
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OXA-14 is another extended-spectrum variant of OXA-10 also identified in 
P. aeruginosa QDanel et al., 1995). It had a pI of 6.2 and differed from OXA-10 by 
only one amino acid residue, which also enabled the host to become resistant to all 
P_lactams except carbapenems. 
OXA-16, OXA-17 and OXA-19 are also extended-spectrum variants of 
OXA-10 and produced by P. aeruginosa (Danel et al., 1998 & 1999; Mugnier et al., 
1998). OXA-16 had the same pI as OXA-14 (pI = 6.2) and conferred resistance to 
ceftazidime although enzyme hydrolysis of the cephalosporin was not detected. The 
amino acid sequence of OXA-16 differed from that of OXA-10 by two positions, 
one of them, ASP157, was also present in OXA-11 and OXA-14 and appeared to be 
responsible for ceftazidime resistance. Both OXA-17 and OXA-19 also conferred 
high-level resistance to most p-lactams except imipenem (Mugnier et al., 1998). 
OXA-17 (pl 二 6.1) rapidly hydrolyzed cefotaxime but hydrolysis of ceftazidime and 
carbapenems was not detectable. The encoding gene differed from that of blaoxA-io 
at one position only ^position 192) causing a change to serine at position 73 of the 
protein (Danel et al, 1999). OXA-19 had a pI of 7.6 and its amino acid sequence 
differed from that of OXA-10 and OXA-13 by nine and two positions, respectively. 
The ASP157 implicated for ceftazidime-resistance was also present in this enzyme. 
In contrast to the above five OXA-type enzymes, OXA-15 is an extended-
spectrum variant of OXA-2 although it was also originally found in P. aeruginosa 
(Danel et aL, 1997). The ceftazidime-resistance in the host strain was not due to 
hyperproduction of chromosomal class C P-lactamase (Livermore, 1995) nor to 
other non-enzymatic resistance (Li et al., 1994). Instead, it was due to a novel 
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enzyme, then designated OXA-15, that readily hydrolyzed ceftazidime. The 
enzyme, which focussed at 8.7 and 8.9, differed from OXA-2 at one amino acid 
position, GLY150. 
Like 0XA-11, OXA-18 is a class D enzyme but it is the first such extended-
spectrum enzyme inhibited by clavulanic acid to be reported (Philippon et al., 1997). 
As with other extended-spectrum OXA-type enzymes, OXA-18 was produced by a 
P. aeruginosa strain that was resistant to ceftazidime, cefotaxime and aztreonam. 
The enzyme rapidly hydrolyzed ceftazidime and aztreonam but the encoding gene 
was not derived from previously known ESBL genes. 
1.3.4.3.6. ESBLs Not Related To TEM-, SHV- Or OXA-Type Enzymes 
Cefotaximases not related to TEM-, SH V- or OXA-type enzymes include CTX-
M-1, (Bauemfeind et al, 1990), MEN-1 (Bernard et al., 1992) and CTX-M-2 
(Bauemfeind et al., 1992). It was found that the amino acid sequences for CTX-M-1 
and MEN-1 were identical while CTX-M-2 was 84% identical to CTX-M-1 and 
MEN-1 (Bauemfeind et al., 1996). These cefotaxime-hydrolyzing ESBLs were 
isolated sporadically from 1989 to 1994 in Europe, South America and Asia (Ishii et 
al” 1995; Bauemfeind et al., 1996). Recently, three novel ESBLs belonging to the 
CTX-M family, CTX-M-3, CTX-M-4 and CTX-M-5 have been identified. CTX-M-
3 was produced by C. freundii strain isolated in Warsaw, Poland in 1996, had a pI of 
8.4 and was very closely related to the CTX-M-lMEN-1 p-lactamase 
(Gniadkowski et al” 1998b). These two ESBLs differed only at four positions of 
their amino acid sequence. 
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CTX-M-4 was produced by a strain of S. typhimurium which caused an 
outbreak in St. Petersburg, Russia (Gazouli et al., 1998b). Like CTX-M-3, this 
enzyme had a pI of 8.4 but it was more closely related to CTX-M-2 (96.9 % 
homology) than CTX-M-1 (80.9 %), differing by eight amino acid residues (Gazouli 
et al, 1998a). One of the substitutions, SER237 ~> ALA, caused a decrease in the 
hydrolytic efficiency against cefuroxime and cefotaxime. 
CTX-M-5 (pI 二 8.8) was also produced by a S. typhmurium strain but this strain 
caused an outbreak in Latvia (Bradford et aL, 1998). The enzyme was very similar 
to CTX-M-2, differing by 4 amino acid residues and the encoding gene being 97.5% 
identical to that of CTX-M-2. 
Other cefotaximases not belonging to the CTX-M family include Toho-1 (Ishii 
et al, 1995) and Toho-2 (Ma et al., 1998). 
ESBLs which confer resistance to cephalosporins including cephamycins are 
known as cephamycinase. CMY-1 was the first of the cephamycinase to be 
identified and it was detected in K. pneumoniae (Bauemfeind et aL, 1989). Other 
than its cephamycin-hydrolzing activity, it differed from other ESBLs by being more 
strongly inhibited by sulbactam than clavulanic acid or tazobactam and had a more 
alkaline pH of 8.0. 
1.3.4.3.7. ESBL And Clinical Significance 
Since the discovery of ESBL in K. pneumoniae in 1983, an increasing number 
of ESBL-producers have been isolated worldwide. These isolates produced different 
types ofESBLs. All ESBLs are able to attack extended-spectrum cephalosporins and 
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monobactams in addition to the narrow-spectrum cephalosporins and penicillins, 
while sparing the carbapenems. However, they vary in the degree of resistance 
conferred. Some, such as TEM-10 and TEM-26, give high-level resistance to 
ceftazidime (MIC > 128 mg/L) but raise the MICs of cefotaxime, ceftriaxone and 
some newer cephalosporins slightly to up to 4 mg/L while others such as TEM-3 and 
SHV-2 give clear resistance to all extended-spectrum cephalosporins and aztreonam. 
Others, e.g. TEM-12, raise the MICs of ceftazidime to only 4 - 8 mg/L and leave 
those of ceftriaxone and cefotaxime to susceptible levels (0.06 - 0.25 mg/L). 
Although these strains appear to be susceptible according to the NCCLS breakpoints 
(< 16 mg/L) they are in fact up to 100-fold less susceptible than those strains that do 
not produce these enzymes. Infections caused by such ESBL-producers usually do 
not respond to treatment by the extended-spectrum cephalosporins except in urinary 
tract infection (Brun-Buisson et al., 1987). Thus, such strains should be regarded as 
resistant to all extended-spectrum cephalosporins and the infections caused be 
treated with other p-lactams that are not affected by these enzymes or with members 
of other families of antimicrobial agents. 
It had been advocated that the use of third-generation cephalosporins or 
aztreonam was an important factor for the development and spread of ESBL-
producers since it exerted substantial selection pressure for these organisms as well 
as for the evolution of ESBLs (Collatz et aL, 1990; MacDonald et a/.,1991; Garau, 
1994). This is understandable since ESBL-encoding genes are usually bome on 
transferable plasmids thereby facilitating their spread. What is more worrying is that 
these plasmids also code for resistances to other antibiotics. Clinicians would be 
31 
Chapter 1 Introduction 
faced with considerable therapeutic problems when infections caused by such 
organisms continue to rise. Thus, the strategy in combating ESBL-producers would 
be to prevent the development of such organisms rather than to use more powerful 
drugs against them. As such organisms are particularly prevalent in intensive care 
units in the hospitals, more effort should be made, e.g. to devise effective infection 
control policies, to diminish their appearance in the hospital. 
Despite the apparently overwhelming number of reports of novel ESBLs 
appearing in the literature, the prevalence of ESBL-producers was not high. A study 
carried out from 1987 to 1991 in a hospital in Madrid, Spain，showed that only 0.4% 
of the 17,049 isolates examined produced ESBLs (Martinez-Beltran et al, 1990). In 
the four months of 1991, 26 hospitals in France collected 9,038 isolates and only 0.9 
% of these exhibited ESBL activity (Goldstein et al, 1993). Another survey which 
was carried out in the United Kingdom in 1990 and 1991 involving 96 hospitals 
showed that amongst 3,951 unselected isolates of Enterobacteriaceae, 1 % produced 
ESBLs (Piddock et al., 1997). 
A more recent large-scale study on the prevalence of ESBL-producing 
klebsiellae from intensive care units involving 35 centers in Europe was carried out 
in 1994 (Livermore & Yuan，1996). It showed that 23 % of 966 klebsiellae were 
putative ESBL-producers. This probably reflected the high prevalence of ESBLs 
amongst klebsiellae rather than the prevalence rate amongst all enterobacterial 
species. However, results of this study indicated that the incidence of ESBL-
producers was increasing. This can also be seen from results of two more recent 
studies. One study which was carried out in Poland in 1995 showed that 20% of K. 
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pneumoniae and 5 % of E. coli were resistant to ceftazidime (Hryniewicz et al, 
1996). Another study was carried out in two months of 1997 in Seoul, Korea. This 
study showed that about 5 % of 290 E. coli produced ESBLs (Pai et al., 1999). 
ESBL-producers have been reported to cause outbreaks in many parts of the 
world. The epidemiology of these outbreaks was often complex and could only be 
elucidated by investigation using molecular techniques. Results of such 
epidemiological investigation have been published and several interesting features 
could be seen. Firstly, outbreaks which frequently occurred in a particular ward of 
the hospital was often caused by one or two epidemic strains, that is, the spread of 
strains belonging to a limited number of clones (Gouby et al., 1994; Hibbert-Rogers 
et aL, 1995; Neuwirth et al, 1996; Palucha et al., 1999). These outbreaks were 
caused by transfer of the epidemic strains amongst patients within the same ward or 
sometimes geographically distant from the outbreak wards, e.g. patients transported 
to other parts of the hospital for X-ray examinations, physio-therapy, etc., thereby 
spreading the organisms throughout the hospital (Gouby et al, 1994). Secondly, 
outbreaks might be interspersed with sporadic cases caused by non-epidemic strains 
probably due to spread of resistance genes carried on a plasmid which was 
transferred to other organisms (Eingen et al, 1993; Prodinger et aL, 1996). In these 
situations, spread of an endemic plasmid rather than an organism had occurred. A 
more intriguing situation would be the spread of a resistance gene that was bome on 
a transposon that transposed to different plasmids (Sirot et al, 1991). Thus, plasmid 
profile analysis and pulsed-field gel electrophoresis would indicate that an outbreak 
had been caused by genetically unrelated strains. 
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Finally, point mutations which lead to one or more amino acid changes and thus 
modification of the type of enzyme can explain why apparently identical strains (as 
demonstrated by molecular techniques such as ribotyping and pulsed-field gel 
electrophoresis of restricted DNA fragments) can produce different types of ESBLs 
(Arlet et al, 1994; Yuan et al., 1998). 
The observation by Gouby and colleagues (1994) that ESBL-producing isolates 
recovered from infected patients were similar to those from asymtomatic patients in 
the same ward was most disturbing. This together with great diversity amongst 
ESBL-producers caused by genetic events mentioned above indicated that ESBL-
producers had become endemic. The problem of control is augmented, as such 
endemic organisms are less likely to be controlled by measures designed to prevent 
spread from a single source. 
1.4. Methods For The Characterization Of p-Lactamases 
p-Lactamases have been traditionally identified by their isoelectric points ^>Is) 
and a limited substrate hydrolysis profiles. As more and more enzymes are 
described, such methods no longer suffice to distinguish them. Different enzymes 
may have the same pI, e.g. TEM-2 and TEM-5 both have a pI of 5.6. Thus, the 
present trend is towards the expansion of the substrates to be tested for the 
hydrolytic activity of the enzymes and ultimately to sequence the encoding genes. 
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1A. 1. Biochemical Methods 
1.4.1.1. Iso-Electric Focusing (IEF) 
p-Lactamases are charged protein molecules, the net charge of which varies 
with the pH of the environment. Therefore, if they are placed under a pH gradient 
they will migrate to a defined pH where the net charge is zero. This point is known 
as the isoelectric point (pI). The pI of a p-lactamase can be determined by placing 
the enzyme in a stable pH gradient in which the pH increases towards the cathode. 
When it is placed at a pH higher than its pI, it will have a negative net charge. If an 
electric current is applied through the gradient, it will move towards the anode, 
thereby increasing its net charge until it reaches its pI position when the net charge is 
zero and it will cease to migrate. If it is placed at a pH lower than its pI, it will move 
towards the cathode and stop at its pI position. This method of determination of pI is 
known as isoelectric focusing (IEF). 
A stable pH gradient is brought about by ampholine, which is a mixture of 
amphoteric substances with pI values arranged over a specified pH range. These 
amphoteric substances or carrier ampholytes will arrange themselves according to 
their pIs, with the lowest pIs at the anode and the highest ones at the cathode, in an 
electric field. 
Many different plasmid-mediated P—lactamases have been described in Gram-
negative bacteria. They have different isoelectric points (pIs) and molecular weights 
and are well established. Thus isoelectric focusing (IEF) is one of the methods used 
to identify p-lactamases fMatthew, 1979) 
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1.4.1.2.Kinetic Studies 
1.4.1.2.1. Rate Ofp-Lactam Hydrolysis 
The rate of hydrolysis of P-lactams can be determined by spectrophotometric 
assays. Since the reaction is accompanied by a decrease in ultraviolet (UV) 
absorption, such a change with time can serve as a progress of the reaction. 
Enzyme is added to a p-lactam solution and the change in UV absorbance is 
monitored in a spectrophotometer. The progress of this reaction is compared to a 
blank that comprises only of the enzyme. Progress curves of such assays are 
analyzed by the computer to give the hydrolysis rate and Michaelis constants 




Km + S 
Where: V is the hydrolysis rate 
Vmax is the maximum rate attainable 
S is the substrate concentration (i.e. P-lactam) 
Km is the Michaelis constant which is the substrate concentration that 
will be hydrolyzed at 0.5 Vmax 
1.4.1.2.2. Inhibition Of P-Lactamase Activity 
The ability of a compound (or inhibitor) to inhibit a P-lactamase can be 
determined by performing P-lactamase assays. Briefly，enzyme is mixed with an 
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inhibitor and then incubated. After incubation, substrate is added and the change in 
absorbance is monitored. A blank that contains enzyme and inhibitor and buffer 
instead of substrate is also set up. The percentage inhibition is calculated by 
comparing the inhibition of the test and the blank. 
The inhibitory activity of an inhibitor on an enzyme is best indicated by I50 
which is the concentration that inhibits 50% of the activity of the enzyme quantified 
(Bush, 1989a). It can be determined by varying the concentrations of the inhibitor 
but using a fixed substrate concentration in the inhibition assay. 
1.4.1.2.3. Specific Activity And Efficiency Of Hydrolysis Of P-Lactamase 
The specific activity of P-lactamase is the number of enzyme units per 
milligram protein of a given extract. After the activity of the enzyme is determined 
as described in 1.4.1.2.1. above, it is standardized against the protein concentration 
of the enzyme extract which can be determined by using various commercial kits. 
This is an indication of the quantity of enzyme produced by the bacterial culture. 
Resistance is often due to the large amount of enzyme produced (Livermore et al, 
1986; Livermore, 1993) rather than to the type of enzyme. It is therefore important 
to determine the specific activity of a particular P-lactamase. Since there may be 
variations in the conditions of each enzyme assay, kinetics of different enzymes are 
often compared by the ratio of Vmax:Km. This ratio is known as "physiological 
efficiency" (Pollock, 1965) or "efficiency ofhydrolysis" (Sykes et al, 1981). 
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1.4.2. Detection Ofp-Lactamase Genes 
1.4.2.1. Hybridization With DNA Probes 
I 
As ESBL arises due to point mutations of one or more nucleotides within the 
encoding gene, the trend is now towards the detection of p-lactamase genes using 
DNA probes. Fragment probes (Sambrook et al., 1989), oligonucleotide probes 
(Mabilat & Courvalin, 1990) and probes prepared by PCR can be used. Target 
DNAs from bacterial strains localized on a positively-charged nylon membrane are 
hybridized with DNA probes which are radioactively-labeled, biotinylated, or 
digoxigenin-labeled. Hybridized signals can be detected by exposure to X-ray films, 
or by immuno-enzymatic detection (Fliss et al., 1995). 
1.4.2.2. Amplification Of Target DNA By Polymerase Chain 
Reaction (PCR) 
The presence of a P-lactamase gene can also be detected by amplification with a 
pair of primers specific for the particular gene. After amplification by PCR, the 
product is subjected to agarose gel electrophoresis. Presence of a band of the same 
size as a positive control indicates a positive reaction. 
1.4.2.3. Polymerase Chain Reaction - Single Strand 
Conformational Polymorphism (PCR-SSCP) 
A positive PCR would only indicate the presence of the gene specified by the 
primers. However, it would not detect mutations within the gene sequence. 
Polymerase chain reaction - single strand conformational polymorphism (PCR-
SSCP) can be used for this purpose. The principle is based on the difference in the 
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migration of small single-stranded DNA molecules in non-denaturing gels due to 
conformational changes brought about by point mutations (Orita et al., 1989). 
Target DNA is subjected to PCR and the amplified fragment is digested with 
restriction enzyme. The digested fragments are then denatured to yield single-
stranded DNA fragments that are separated in neutral polyacrylamide gel (Orita et 
al., 1989; M'Zali et al, 1996). The pattem generated is compared with that of strains 
known to harbor the particular gene. 
1.4.2.4. DNA Sequencing 
Although PCR-SSCP is able to detect presence of mutations within the gene, it 
does not provide information on the nucleotide change that occurred. The only 
method for identification of such change is to sequence the gene in question 
(Ausubel & Albright, 1998). DNA sequencing not only allows determination of the 
nucleotide sequence of the gene, it can also lead to the deduction of the protein 
sequence. The position of amino acid substitution was vital to the expansion of the 
substrate profile of the enzyme (Gniadkowski et aL, 1998; Matsumoto & Inoue, 
1999;Wue/ aL, 1999). 
1-5. Objectives 
ESBL-producers have been reported in many parts of the world, however, there 
has not been any detailed study of such organisms in Hong Kong. The present study 
aims: 
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1. To characterize p-lactamases produced by clinical isolates of members of 
the family Enterobacteriaceae that were resistant to the extended-spectrum 
cephalosporins from patients in the Prince of Wales Hospital in 1996; 
2. To determine the genetic basis of such p-lactam-resistance by genetic and 
molecular studies; and 
3. To detect and characterize novel p-lactamases by biochemical methods. 
It is hoped that by this study, we will have a better understanding of the 
mechanisms of resistance to the extended-spectrum cephalosporins in 
enterobacterial organisms in Hong Kong. This can be used as a basis for future 
strategies on the prevention of development and spread of antibiotic resistance to be 
devised. 
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Materials & Methods 
2.1. Bacterial Isolates 
One hundred and sixty-three ceftazidime-resistant clinical isolates of 
enterobacteria were collected in 1996 at the Prince of Wales Hospital, Hong Kong. 
These isolates were screened by the double disk diffusion test (Jarlier et al., 1988) 
for the detection of synergy between ceftazidime and clavulanic acid. A total of 60 
strains which showed a positive double disk diffusion test and survived were 
studied. 
Isolates were stored on nutrient agar fNFA) (Oxoid, Basingstoke, England) slants 
at ambient temperature and in glycerol broth and stored at -20°C. Bacteria were 
recovered from storage by subculturing on MacConkey agar (Oxoid) or inoculating 
into Brain Heart Infiision (BHI) broth (Oxoid). 
2.2. Antimicrobial Agents & Materiate Used In This Study 
Media, chemicals and antibiotics used in this study (TABLES 2-1 & 2-2) were 
either from commercial suppliers or were gifts from the manufacturers. All 
antibiotic disks used in this study were purchased from Oxoid. 
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TABLE 2-1: Antibiotics used in this study 
Antibiotic & Inhibitor Source 
Amikacin Sigma, ST, Louis, MO, USA 
Ampicillin Sigma 








Clavulanic acid SmithKline Beecham，USA 
Gentamicin Sigma 
Imipenem Merck, Sharpe & Dohme，Frankfuther Stmsse, Gemany 
Meropenem Zeneca Pharmaceuticals Group, Wilmington, USA 
Netilmicin Sigma 
Nitrocefin Oxoid 
Ofloxacin Daiichi Pharmaceutical, Tokyo, Japan 
Penicillin G Sigma 
Piperacillin Sigma 
Rifampicin Sigma 
Tazobactam Lederle Piperacillin Inc., Carolina, Puerto Rico, USA 
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TABLE 2-2: Media and chemicals used in this study 
Brain heart infusion (BHI) broth Oxoid, Basingstoke, Hampshire, UK 
Iso-sentitest (IST) agar Oxoid 
MacConkey agar Oxoid 
Media Mueller-Hinton agar Oxoid 
Nutrient agar Oxoid 
Nutrient broth Oxoid 
Phosphate-buffered saline Oxoid 
Absolute alcohol Merck, Frankfiither Strasse, Germany 
Agarose gel Sigma 
Ammonium sulphate Sigma 
Boric acid Sigma 
Bovine serum albumin Sigma 
Bromophenol blue Sigma 
Chloroform Gibco BRL 
Deoxynucleotide triphosphates Sigma 
Ethidium bromide Sigma 
Ethylenediaminetetraacetic acid Sigma 
(EDTA) 
Ficoll (Type 400) Pharmacia LKB Biotechnology, 
Uppsala, Sweden 
Glacial acetic acid Sigma 
Glucose Sigma 
^ , . 1 Glycerol Sigma 
cttemicais Hydrochloric acid Sigma 
Isoamyl alcohol Merck 
Isopropanol Merck 
Magnesium chloride (MgCl2) Sigma 
Maleic acid Sigma 
Nitrocefin Oxoid 
Phenol Gibco BRL 
Potassium chloride Sigma 
Potassium acetate BDH, Poole, England 
Proteinase K Sigma 
Sodium chloride QSfaCl) Sigma 
Sodium citrate Sigma 
Sodium dodecyl sulphate (SDS) BDH 
Sodium hydroxide O^aOH) BDH 
Sodium pyrophosphate Sigma 
Tris-base Sigma 
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2.3. Antimicrobial Susceptibility Testing 
2.3.1. Double-Disk Diffusion Test 
Commercially prepared antibiotic disks were applied to the surface of a 
Mueller-Hinton (MH) agar plate that had been inoculated with a bacterial 
suspension. The inoculum was prepared by inoculating ovemight colonies in sterile 
saline to a turbidity matching that of a MacFarland 0.5 standard (equivalent to 
o 
bacterial concentration of approximately 1.5 x 10 cfu/mL). A fixed volume of 100 
jiL of the suspension was transferred to the agar plate and spread evenly on the agar 
surface using a sterile glass rod. Paper disk containing both amoxicillin and 
clavulanic acid (20/10 ^g) was placed in the middle of the plate while ceftazidime 
(30 |ag), cefotaxime (30 ^g) and ceftriaxone (30 |ig) disks were placed at the 
periphery, with a 20-30 mm distance from the disk at the center (Thomson and 
Sanders, 1992). 
The agar plates were incubated ovemight at 37°C and zones of inhibition were 
then measured. Presence of synergy was defined as an enlarged inhibition zone of 
ceftazidime, cefotaxime or ceftriaxone towards the amoxicillin/ clavulanate disk, 
2.3.2. Determination Of Minimal Inhibitory 
Concentrations (MICs) 
Minimal inhibitory concentrations (MICs) were determined by an agar dilution 
method QS[ational Committee for clinical laboratory Standards QSfCCLS), 1993). MH 
agar plates containing serial two-fold dilutions of antibiotics were prepared (TABLE 
2-3). Each bacterial strain to be tested was inoculated in 2.0 mL BHI broth and 
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incubated for 4 hours to late log phase. The bacterial concentration was adjusted in 
sterile 0.9% saline to a turbidity matching that of a MacFarland 0.5 standard, diluted 
10-fold and used as the inoculum. MIC-2000 inoculator (Dynatech Instrument, Inc., 
California, USA) was used to deliver approximately 10,000 colony forming units 
onto antibiotic-containing plates. The agar plates were incubated at 37°C for 18 
hours. The lowest concentration of antibiotic that inhibited growth of the strain was 
taken as the minimal inhibitory concentration. 
2.4. Characterization Of Resistance Plasmids 
2.4.1. Genetic Study 
This experiment aimed to examine whether plasmids that conferred antibiotic 
resistance to a bacterial strain (R-plasmids) were auto-transferable or not. Both the 
resistant test strain, the donor, and a standard strain which was sensitive to all 
antibiotics except one to which the donor was susceptible (the resistance was bome 
on the chromosome), the recipient, were cultured together. Transconjugants 
(recipient strains which had acquired drug resistance plasmids from the donor 
strains) were counter-selected on agar plates containing an antibiotic to which the 
donor was resistant and another to which the recipient was resistant. 
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TABLE 2.-3: Antibiotics and range of concentration tested 
Antibiotics Concentration Range (mg/L) 
P"Lactams 
Ceftazidime 0.0075 - 1024 
*Ceftazidime + clavulanate 0.0075 — 8 
Piperacillin 0 . 3 - 1024 
本* 
Piperacillin + tazobactam 0.3 — 256 
Cefuroxime 0 .03- 1024 
Cefoxitin 0.03 - 1 0 2 4 
Ceftriaxone 0.03 - 1024 
Cefotaxime 0 .03-1024 
Aztreonam 0.03 - 1024 
Imipenem 0.0075 - 8 
Meropenem 0.0075 - 8 
Aminoglycosides 
Gentamicin 0.03 — 256 
Netilmicin 0.03 - 256 
Amikacin 0 .03-256 
Quinolones 
Ciprofloxacin < 0.0075 - 256 
Ofloxacin 0.0075-256 
* Ceftazidime； + 4 mg/L clavulanic acid 
Piperacillin + tazobactam (8:1) 
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Donor and recipient strains were grown separately with shaking at 37°C for 4 
hours to late exponential phase in BHI broth. Equal volumes (1 mL) from each broth 
were mixed to give the conjugation mixture, which was then incubated at 37°C 
overnight without aeration. 
Ten-fold dilutions of the mixture were made and 0.1 mL each from the neat, 10' 
1, 10.2，and 10_3 dilutions was plated on MacConkey agar containing ampicillin (128 
^g/mL) and rifampicin (128 ^g/mL). To determine the number of recipient cells, 0.1 
r 7 Q 
mL each from the 10"，10" , and 10" dilutions of the conjugation mixture was plated 
on plain MacConkey agar. The number of colonies corresponding to the phenotypic 
property of the recipient strain on the selective media and plain MacConkey agar 
were counted and calculated to give the number of transconjugant and recipient 
colonies, respectively, per mL. The transfer frequency was taken as the number of 
transconjugant colonies per recipient celL 
The antibiotic susceptibility of the transconjugants was tested by an agar 
dilution method as described previously (2.3.2.) except that break-point 
concentrations of antibiotics were used: ceftazidime (2 mg/L), cefotaxime (2 mg/L), 
ceftriaxone (2 mg/L), cefuroxime (4 mg/L), gentamicin (1 mg/L), aztreonam (1 
mg/L) and ciprofloxacin (1 mg/L). Bacterial strains were regarded as resistant if 
there was growth on the inoculation spot. 
2.4.2. Molecular Studies 
The number and size of plasmids present in an isolate were determined by 
electrophoretic separation of extracted plasmids on agarose gel. 
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2.4.2.1.Extraction Of Plasmids 
Plasmids were extracted from the selected strains by the alkaline lysis method 
(Sambrook et al., 1989). A single bacterial colony was inoculated into 2 mL ofBHI 
broth containing 100 p,g/mL ampicillin in a loosely capped 10 mL tube, which was 
then incubated at 37�C with agitation. After ovemight incubation, 1.5 mL of the 
culture was transferred into a microcentrifuge tube and was centrifuged at 12,000 
rpm for 2 minutes at ,4°C in a microcentrifuge (Biofuge 22R, Heraeus Sepatech, 
Osterode, West Germany). The supernatant was aspirated and the cell pellet was 
resuspended in 100 i^L of ice-cold Solution I (TABLE 2-4) by vigourous vortexing. 
A total of 200 i^L of freshly prepared Solution II (TABLE 2-4) was added to the 
microfuge tube. The content was mixed by inverting the microfuge tube five times 
and then stored on ice. Ice-cold Solution III (TABLE 2-4) was then added to the 
microfuge tube and vortexed gently. The tube was left on ice for 3-5 minutes and 
then centrifuged at 15,000 rpm at 4°C for 10 minutes. 
An equal volume of phenol:chloroform (1:1) was added to the content of the 
microfuge tube and mixed by vigorous vortexing. After centrifuging at 15,000 rpm 
at 4°C for 10 minutes, the supernatant was transferred to a fresh microfuge tube. 
DNA was precipitated by mixing with 2 volumes of absolute ethanol and 
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TABLE 2-4: Components of the lysis solution 
Solution Contents 
I 50 mM glucose, 25 mM Tris-HCl (pH 8.0) 10 mM EDTA 
Q)H 8.0), autoclaved 
II 0.2 N NaOH, 1 % SDS, in situ preparation 
爪 60 mL 5 M potassium acetate, 11.5 mL glacial acetic acid, 
28.5 mL H2O 
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stored at -70°C for 2 hours. The microflige tube was then centrifuged at 15,000 rpm 
at 4°C for 10 minutes and the supernatant was discarded. The DNA pellet was 
washed 2 times with 70% ethanol, dried in a Speed-Vac (Savant Instrument Inc., 
Farmingdale, N.Y., USA) for 15 minutes, redissolved in 200 juL of double-distilled 
water and stored at -20°C or used immediately. 
2.4.2.2. Agarose Gel Electrophoresis 
Plasmid DNA (10 ^L) was mixed with 2 i^L 6x loading buffer (0.25 % 
bromophenol blue and 15 % Ficoll type 400) and loaded into wells of a piece of 
0.7% agarose gel in a horizontal gel apparatus (GNA200, Pharmacia, LKB) in a 
Tris-borate-EDTA (TBE) buffer system. Electrophoretic separation was performed 
at 100V for 4.5 hours. After electrophoresis, the gel was stained with 0.5 ^g/mL 
ethidium bromide for 30 minutes and plasmid bands were photographed under 
ultraviolet illumination using a Polaroid MP4 Land Camera (Polaroid) and Polaroid 
T667 (Polaroid, USA) black and white films through a red filter (HOYA, Tokyo, 
Japan) with an aperture of 8 for 10 seconds. Distance between the plasmid band and 
the well of the gel was measured. Since the distance travelled by a plasmid is 
inversely proportional to its size, the size of the plasmids could be estimated from a 
graph of the logarithm of the distance travelled by plasmids of known size versus 
their molecular size (Meyers et al, 1976) or by using a computer program (Ling et 
aL, 1987). Plasmids of known size that were used as standards, were 40R646 
(58.14kb), 40R268 (98.43 kb), 40R448 (119.35 kb)，28R626 (61.52 kb) and RT641 
(91.36 kb) (gift from Dr. B. Rowe, Division of Enteric Pathogens, Central Health 
Laboratory, London, UK). 
50 
Chapter 2 Materials & Methods 
2.5. Characterization Of p-Lactamases 
2.5.1. Preparation Of Crude & Pure j3-Lactamases 
All strains were grown overnight at 37°C on IST agar containing 32 mg/L 
cefotaxime. Several colonies were picked, inoculated into IST broth in two conical 
flasks (3 liters each) and then incubated overnight at 37°C with shaking on a rotary 
shaker ^S[ewBrunswick Scientific, N.J. U.S.A.) at 180 r.p.m. Cells were harvested 
by centrifugation at 6,000 r.p.m. (Hitachi CR 20B3, Japan) for 30 minutes at 4°C. 
The cell pellet was washed twice with 0.05 M phosphate buffer Q)repared by mixing 
39 mL of 0.2 M of sodium phosphate, NaH2PO4.2H2O and 61 mL of 0.2 M dibasic 
sodium phosphate, Na2HPOri2H2O; pH=7.0), stored at -70�C for 8 hours and then 
thawed at 4°C for 6 hours. Intracellular P-lactamases were obtained by disruption of 
the bacterial homogenate by sonication in a Sonifier (VWR Scientific, USA). Each 
sonication process was carried out at 4°C for 2 minutes with a 1-minute interval or 
until an opaque, milky bacterial homogenate was seen. Cell debris was removed by 
centrifugation at 6,000 r.p.m. (Hitachi CR 20B3) for 20 minutes at 4°C. A viable 
count of bacteria in the homogenate was performed to determine the efficiency of 
cell breakage. p-Lactamase activity in the cell extract was tested by a chromogenic 
substrate, nitrocefin (0.5 mg/L) (Oxoid). 
Cmde p-lactamase extracts were precipitated and concentrated by ammonium 
sulphate and then purified by column chromatography. 
P-Lactamases were precipitated by ammonium sulphate at 85% saturation. 
Anhydrous ammonium sulphate powder was added slowly to the cell extract to a 
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concentration of 0.75 g/mL. The mixture was stirred at 4°C for 1 hour and then 
centrifuged (Hitachi CR 20B3) at 3200g at 4°C for 45 minutes. The supernatant was 
discarded and the pellet was resuspended in 5 mL of 0.05 M phosphate buffer 
(pU=7.0y 
The precipitated ,P-lactamase suspension was loaded onto a 1-meter long 
column (Pharmacia Biotech Biotechnology, Uppsala, Sweden) containing Sephadex 
GlOO (Pharmacia) and,eluted with 0.05M phosphate buffer (pH=7.0) in a downward 
flow manner. The eluent was collected in fractions of 50 drops each by a fraction 
collector (RediFrac, Code No. 18-1003-64, Pharmacia, Uppsala, Sweden). Fractions 
collected were tested with nitrocefin (Oxoid) for p-lactamase activity. 
2.5.2. Isoelectric Focusing 
Crude enzyme preparations were used for isoelectric focusing (Matthew & 
Harris, 1976). Isoelectric focusing was performed on the Multiphor II 
Electrophoresis System (Pharmacia Biotech AB, Uppsala, Sweden) using 
Ampholine® PAG plates (pH = 3.5 - 9.5, Pharmacia). Enzymes extracted from 
strains known to produce TEM-1, TEM-2, SHV-1, SHV-4, SHV-5 and P99 were 
used as standards. The running conditions were 500 V, 100 mA and 10 W for 4 
hours at 4 °C. After isoelectric focusing, p-lactamases were detected by placing a 
piece of filter paper soaked with nitrocefin solution (50 ^ig/mL) on the gel surface. A 
curve of isoelectric points ^>Is) of the standards versus their distances from the 
cathode was plotted and pIs of P-lactamases under investigation were read-off from 
the curve. 
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2.5.3. Enzyme Kinetics 
2.5.3.1.Substrate Profiles 
Five enzymes were purified as described above and characterized by 
determining their substrate profiles, TEM-3 enzyme was used as a control. The 
enzyme assay was performed by measuring the change in absorbance at the 
appropriate wavelength for each substrate at 37°C in a spectrophotometer (Lambda 
Platform Instruments, Perkin Elmer Corp., Norwalk, CT, USA), The wavelengths 
and substrates used were as follows: 235 nm for benzylpenicillin and ampicillin, 295 
nm for cephaloridine, 255 nm for cefotaxime, 257 nm for ceftazidime, 297 nm for 
imipenem and 315 nm for aztreonam. Enzyme activity was determined in a total 
volume of approximately 1 mL (1 mL substrate + 20 ^L enzyme). A fixed substrate 
concentration in 0.05 M phosphate buffer, pH=7.0 was used. Substrate blanks 
(without enzyme only) were recorded for each reaction. Initial rate of substrate 
hydrolysis for each enzyme was measured at different substrate concentrations. The 
ranges of substrate concentrations tested (in serial two-fold dilutions) are shown in 
TABLE 2-5. 
Substrates and enzymes were first pre-wamied separately at 37°C for 10 
minutes. The pre-warmed enzyme was then added to the substrate and hydrolysis 
was immediately monitored at 37°C in the spectrophotometer and the initial rates 
were taken. The initial rates of substrate hydrolysis were analyzed by the 
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I 
TABLE 2-5: Substrates and their concentration range used in the kinetics study 
Substrate Concentration Range (^M) 
Ampicillin 2 - 1 0 2 4 
Aztreonam 2 - 1024 
Cefotaxime 2 - 1 0 2 4 
Ceftazidime 2 - 1 0 2 4 
Cephaloridine 2 - 1024 
Imipenem 2 - 1024 
Penicillin G (benzylpenicillin) 2 — 1024 
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Lineweaver-Burk plot of \N against l/[S] (Livermore & Williams, 1996). This plot 
allows the estimation of specific Vmax and Km. The relative Vmax rates for all the 
substrates were compared with that of penicillin G (benzylpenicillin) which was 
taken to be 100%. The enzymatic unit is the amount of enzyme which hydrolyses 1 
mM of substrate per min at 37°C，pH=7.0. The specific activity is defined as the 
number of enzyme unit per milligram protein of a given extract. 
2.5.3.2.Inhibition Studies 
Clavulanic acid was used as the inhibitor in this study. The initial rate of 
hydrolysis of a given reaction at a stated enzyme concentration was measured. A 
total of 30 [iL of enzyme was added to a range of concentrations (2-1024 ^M in 
serial two-fold dilutions) of inhibitor in 100 ^L phosphate buffer, pH=7.0, and the 
total volume was made up to 200 p,L with double distilled water and incubated at 
37°C for 10 minutes. The enzyme-inhibitor mixture was then added to 1 mL of 
phosphate buffer (0.05 M, pH=7), which contains each of the antibiotics at the 
antibiotic concentrations shown in TABLE 2-5. Hydrolysis was immediately 
followed and monitored at 37°C in the spectrophotometer. I50 was the concentration 
of inhibitor required to reduce the activity of the enzyme to 50% of that achieved in 
the absence of an inhibitor. 
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2.6. Characterization Of p-Lactamase Genes 
2.6.1 Detection Of TEM- & SHV-Type fi-Lactamase 
Genes By PCR 
The presence of TEM- or SHV-type p-lactamase genes was detected by PCR 
using TEM- or SHV-type specific primers. 
2.6.1.1.Total DNA Preparation 
Total DNA preparation was performed according to a standard protocol 
(Ausubel & Albright，1998). Bacterial strains were grown ovemight at 37°C on IST 
agar (Oxoid). Three loopfuls of bacteria were scraped from the surface of the IST 
agar plates and emulsified in 1.5 mL double-distilled water in an eppendorf tube. 
The bacterial emulsion was centrifuged at 13,000 r.p.m. for 20 seconds at 4°C in a 
micro-centrifuge (Tomy Capsule, HF-120, Tomy Seiko Co., Ltd. Tokyo, Japan.). 
The cell pellet was resuspended in 567 ^1 Tris-EDTA (TE) buffer (pH = 7,5) and 30 
i^L proteinase K (20 ^g/mL) (Gibco BRL, New York) and incubated for 1 hour at 
37°C. One hundred microlitres of 5 M NaCl were added. The mixture was incubated 
for 10 minutes at 65°C. An equal volume of chloroform/isoamyl alcohol (24:1) was 
added, mixed and centrifuged in a micro-centrif\ige for 5 minutes at 13,000 r.p.m. 
The aqueous phase was then transferred to a fresh eppendorf tube and mixed with an 
equal volume of phenol/chloroformAsoamyl alcohol (25:24:1). The mixture was 
centrifuged in a micro-centrifuge for 10 minutes at 13,000 r.p.m. The aqueous phase 
was aspirated and mixed with 0.6 volume of absolute ethanol to precipitate DNA. 
The mixture was stored at -70°C for 2 hours and centrifuged for 15 minutes at 
13,000 r.p.m. in a micro-centrifuge and the DNA pellet was washed with 70% 
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ethanol. After centrifugation for 20 minutes at 15,000 rpm, ethanol was removed and 
the pellet was allowed to dry at ambient temperature for 3 hours. The DNA pellet 
was resuspended in 100 mL TE buffer containing 20 ^ig/mL RNase (Gibco BRL). 
2.6.1.2.PCR Assay 
Total DNAs extracted as described above were used as templates for PCR. Five 
pairs of oligonucleotide primers (Gibco BRL) were used (TABLE 2-6). Primers la 
and lb are specific for bla^^u gene while primers 2a and 2b — 5a and 5b are specific 
for bIasm gene. 
Amplification reactions were done in a thermal cycler (PTC-100, M.J. 
Research, Inc., USA) in 50 foL volume, each containing 1 unit Taq polymerase 
(Gibco BRL), lx PCR reaction buffer (10 mM Tris-HCl, pH=8.3, 1.5 mM MgCl2, 
50 mM KC1, 200 \xM each of the deoxynucleoside triphosphates), 1 nmole of each 
of a pair of TEM-type or SHV-type primers and 5 ^L of template DNA. PCR was 
performed for 30 cycles each at 94°C for 1 min, 55°C for 1 min and 72°C for 1 min. 
2.6.1.3.Agarose Gel Electrophoresis 
PCR products were separated electrophoretically on 1 % agarose (Sigma). 
Samples (15 ^iL) mixed with 3 i^l loading buffer (6x) were loaded into wells of an 
agarose gel and electrophoresed in an electrophoresis cell (GNA 2000) in a TBE 
buffer system (2.4.2.2.) at 100 volts for about 4 hours. The gel was stained and 
photographed as described previously (2.4.2.2.) 
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TABLE 2-6: Oligonucleotide primers used for amplification of blajEwi 
and blasHV genes 
Primer Nucleotide Sequences References 
la: TEM-1079 ^,_ 八丁八 AAA TTC TTG AAG ACG AAA -3’ 
Forward 
Mabilat & Courvalin, 1990 
lb: ^ M - 1 0 7 9 5’_ GAc AGT TAC CAA TGC TTA ATC A -3’ 
Reversed 
Oo. <VRV Ron 
^ 7 5'- GGG TTA TTC TTA TTG TCG C - 3 ' Forward 
Rasheed etal, 1997 
2b: SHV-800 5,_ 丁丁八 Q^G TTG CCA GTG CTC - 3 ' 
Reversed 
3a: SHV-292 ,^_ 八匸丁 GAA TGA GGC GCT TCC -3’ 
Forward 
Prodinger et al., 1996 
3b: SHV-292 5,- 丁匸^  cGC AGA TAA ATC ACC A - 3 ' 
Reversed 
4a- SHV-475 
^ 二 5'- TCA GCG AAA AAC ACC TTG - 3 ' Forward 
M'Zali etal, 1996 
4b- SHV-475 
^ . 5'- TCC CGC AGA TAA ATC ACC A - 3 ' Reversed 
5a: SHV-649 5' . QCG AAA GCC AGC TGT CG - 3 ' 
Forward 
Piddock etal., 1997 
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26.2. Oligotyping For Characterization Of TEM-Type j3-
Lactamase Genes 
Oligonucleotide probes were selected to detect point mutations in TEM-type p-
lactamase genes. A total of eight probes (Gibco BRL) as shown in TABLE 2-7 were 
used for oligotyping (Ouellette et al 1987, Mabilat & Courvalin 1990). Bacterial 
colonies grown on agar surfaces were transferred to nylon membranes for in situ 
hybridization with individual probes. 
2.6.2.1.Colony Lifts & Cell Lysis 
To transfer bacterial colonies on agar surfaces to nylon membranes and lyse in 
situ, the following steps were preformed. Three pieces of filter paper were soaked in 
either one of the following solutions: denaturation solution (0.5 N NaOH, 1.5 M 
NaCl, 0.1% SDS), neutralization solution (1.0 M Tris-HCl, pH=7.5, 3 M NaCl) and 
2 times SSC (prepared by dissolving 3 M sodium chloride and 0.3 M sodium citrate 
in 10 L of deionised water). Bacterial strains were inoculated onto IST agar using 
the MIC-2000 inoculator (Dynatech Instrument). The agar plate was then incubated 
at 3 7 � C overnight 
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TABLE 2-7: Oligonucleotide probes used for oligotyping 
Probe Oligonucleotide Sequence 
GLN39 5,- CCC AAC TGA TCT TCA -3‘ 
LYS39 5'- CCC AAC TTA TCT TCA -3’ 
GLU104 5'- TGA GTA CTC AAC CAA GT -3’ 
LYS104 5,- TGA GTA CTT AAC CAA GT -3’ 
ARG164 5,- TTC CCA ACG ATC AAG GC - 3 ' 
SER164 5'- TTC CCA ACT ATC AAG GC -3’ 
GLY238 5'- ACG CTC ACC GGC TCC AG - 3 ' 
SER238 5'- ACG CTC ACT GGC TCC AG - 3 ' 
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A piece of positively charged membrane disc (Amersham) was carefully placed onto 
the agar surface and left for 1 minute. It was then lifted using a pair of tweezer and 
was placed colony-side up for 15 minutes on the filter paper that was soaked with 
denaturation solution. The membrane (colony-side up) was blotted on paper towel 
and then transferred onto the filter paper soaked with neutralization solution. The 
membrane was blotted on paper towel, transferred onto a filter paper soaked with 2 
times SSC, and then baked at 80°C for 30 minutes for DNA-membrane crosslinking. 
The membrane (colony blot) was further treated with 0.5 mL of 2 mg/mL 
^ 
proteinase K (0.5 mL for 52.8 cm ) and incubated for 1 hour at 37°C. Cellular and 
agar debris could be removed by placing the membrane between two pieces of filter 
paper soaked with distilled water and then applying pressure over the area with a 
ruler or a bottle. 
2.6.2.2.Labeling Of Oligonucleotide Probes 
Oligonucleotide probes were labeled using the DIG oligonucleotide 3'end 
labeling kit (Boehringer Mannheim). The labeling mixture (TABLE 2-8) was set up 
in a microfuge tube and was incubated at 37°C for 15 minutes followed by cooling 
on ice. The provided glycogen (1 |iL) was added to 200 ^L of 0.2 jaM EDTA and 2 
i^L of this was added to the labeling mixture to stop the reaction. The final volume 
was made up to 50 \iL. The mixture was passed through a microspin column (BIO-
RAD) to remove unlabelled probe and centrifuged at 3,000 r.p.m. for 10 minutes. 
The eluent was retained for future use. 
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) 
TABLE 2-8: Contents of the oligonucleotide labeling mixture 
Item Volume (|iL) 
Tailing buffer+ 4 
C0Cl2+ 4 
Oligonucleotides 10 pmol 
DIG ddUTP+ 1 
Terminal transferase+ 1 
ddH2O Volume added to 
make up the total 
volume to 20 p,L 
+ supplied with the kit. 
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2.6.2.3. Hybridization 
The colony blot was prehybridized for 3 hours at 37°C in 10 mL 
prehybridization buffer which contained 6X SSC, 5X Denhardt's solution, 0.05 % 
sodium pyrophosphate, 100 jig/mL denatured salmon species DNA (boiled at 100°C 
for 10 min.) and 0.5% SDS in a hybridization oven (Autoblot Bellco 
Biotechnology), 
After prehybridization, the buffer was removed and replaced by 10 mL 
hybridization solution (6X SSC, IX Denhardt's solution, 0.05 % sodium 
pyrophosphate, 100 ^ig/mL denatured salmon species DNA and 0.5 ng/mL labelled 
probe). The hybridization process was carried out at 37°C ovemight. 
After hybridization, the membrane was washed with 100 mL of washing buffer 
(5X SSC and 0.05% Na2PO4) twice at 4 °C for 15 minutes each, once at 37°C for 20 
minutes and finally once at 39°C for 15 minutes to remove unbound 
oligonucleotides. 
2.6.2.4. Detection 
Hybridization was detected using the DNA Nucleic Acid Detection Kit 
(Boehringer Mannheim). The membrane was washed briefly in washing buffer 
(TABLE 2-9) containing 0.3% (w/v) Tween 20, and then in about 100 mL ofBuffer 
2 (TABLE 2-9) for 30 minutes at room temperature. The membrane was then 
incubated at 37°C for 30 minutes in 20 mL of diluted antibody conjugate (1:5000 in 
Buffer 2). The unbound antibody conjugate was removed by washing twice for 15 
minutes each in 100 mL ofBuffer 1. The membrane was then 
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TABLE 2-9: Components of each buffer in the DNA Nucleic Acid Detection Kit 
(Boehringer Mannheim) 
Bufferl 0.1 ^ maleic acid, 0.15 M NaCl, pH=7.5 (20�C)，adjusted 
with concentrated NaOH, autoclaved 
^ ^ t o ^ ^ Vial 5 was dissolved in Buffer 1 to a final concentration of 
Solution 10% (w/v) with shaking and heating, autoclaved 
i = f ^ ^ g Buffer 1 with Tween-20, 0.3% (w/v) 
Buffer 2 Blocking stock solution, diluted 1 : 10 in Buffer 1 
100 mM Tris-HCl, 100 mM NaCl, 50 mM MgCl2, pH=9.5 
細 6 " (20°C) 
Buffer 4 10 mM Tris-HCl, 1 mM EDTA, pH=8.0 (20°C) 
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incubated in 10 mL freshly prepared developing solution (200 |iL NBT/BCIP stock 
plus 10 mL Buffer 3 (TABLE 2-9)) until purplish blue color appeared. Five 
microliters ofBuffer 4 (TABLE 2-9) were added to stop the reaction. 
2.6.3. Characterization OfblasHv Gene Using Polymerase 
Chain Reaction-Single Strand Conformational 
Polymorphism (PCR-SSCP) 
Two strains (4565 and 6364) which produced a 475 bp amplimer after PCR 
using the specific SHV primers (4a, b in TABLE 2-6) were subjected to PCR-SSCP 
analysis. Standard strains producing SHV-1 (pl = 7.6), SHV-4 (pl = 7.8) and SHV-5 
(pI = 8.6) were used as controls, 
2.6.3.1. Polymerase Chain Reaction - Single Strand 
Conformational Polymorphism (PCR-SSCP) Analysis 
A 475 bp sequence of the SHV gene was amplified from total DNA of the 
isolates using the 4a, b primers (TABLE 2-6). Each primer (10 nmoles) was mixed 
with 5 ^L of 10x PCR buffer (GIBCO BRL), 0.5 ^L of 25 mM dNTP (GIBCO 
BRL), 2 |iL of50 mM MgCl2 (GIBCO BRL) and 1 U ofTaq polymerase in a sterile 
200 |aL microfuge tube. The amplification mixture was made up to 45 p,L with 
sterile distilled water. Then 50 fxL of DNA template were added to the reaction 
mixture. The template was prepared by emulsifying 4 ovemight colonies on IST 
agar in 50 i^L distilled water and heating the cells at 95�C for 5 minutes on a heat 
block (Tm Temp DNA Microheating System, Robbins Scientific, USA). 
Amplification was carried out in a thermocycler (MJ Research), which consisted of 
35 cycles of denaturation at 94�C for 15 seconds, annealing at 60°C for 30 seconds, 
65 
Chapter 2 Materials & Methods 
extension at 72°C for 1 minute and a final elongation period of 5 minutes at l T C . 
The 475 bp PCR product was then subjected to restriction enzyme digestion or 
stored at 4°C until further analysis. 
The 475 bp amplimer was digested with 5 units of Pst I (GIBCO BRL) 
ovemight at 37°C according to the manufacturer's instructions to produce one 300 
bp fragment and one 175 bp fragment. The digested amplimer (3 p,L) was then 
denatured to yield single-stranded DNA fragments by mixing the digestion product 
with an equal volume of denaturation solution (97% deionised formamide, 4.6 M 
urea, 0.3% bromophenol blue, 0.3% xylene cyanol and 10 mM EDTA). The mixture 
was heated in a thermocycler at 95°C for 5 minutes and then immediately transferred 
to an ice water bath. 
All of the digested-denatured DNA mixture was loaded into a well of the 
) 
ExcelGel (size = 80 cm , ExcelGel DNA Analysis kit, Pharmacia Biotech) and 
electrophoresed on an Electrophoresis System (Multiphor II, Pharmacia Biotech) at 
600 V, 50 mA, 30 W for 80 minutes. The temperature was maintained at 4°C by 
using a MultiTemp III temperature controller (Pharmacia Biotech). 
2.6.3.2.DNA Staining By Silver Stain 
A DNA silver staining kit (Pharmacia Biotech) was used to stain DNA on the 
ExcelGel after electrophoretic separation. The gel was first soaked in 25 mL fixing 
solution (Pharmacia Biotech) for 45 minutes and then in 25 mL silver solution 
(Pharmacia Biotech) for 30 minutes. The gel was washed with 50 mL of deionised 
water for 1 minute and developed in developing solution (Pharmacia Biotech) at 
room temperature for 6 minutes. The reaction was stopped by adding 25 mL of 
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stopping and preserving solution and left at room temperature for 1 hour. The gel 
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Results 
3丄 Bacterial isolates 
A total of 60 surviving enterobacterial isolates amongst 163 isolated in 1996 at 
the Prince of Wales Hospital, Hong Kong which were ceftazidime-resistant were 
studied. These 60 isolates were positive for the double disk synergy test (FIGURE 3-
1). The isolates included Escherichia coli (17), Klebsiella sp. (16), Enterobacter sp. 
(18)，Morganella morganii (7)，and Serratia marcescens (2), They were non-
duplicate isolates from different sites: urines (47), bile (5), dialysis fluid (3), and pus 
(4)andbodyf lu id( l ) . 
3.2. Antimicrobial SusceptibiHty Testing 
The distribution of ceftazidime: ceftazidime + clavulanic acid MIC ratios is 
shown in FIGURE 3-2. A bimodal distribution was noted, with 38.3 % of isolates 
showing MIC ratios of < 16 and 61.7% giving ratios > 16. Isolates with MIC ratios > 
16 were considered to produce ESBLs (Livermore & Yuan, 1996). Fifty-two to 61% 
of those for which ceftazidime: ceftazidime + clavulanate ratio was < 16 were 
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Chapter 3 Results 
The susceptibilities of the 37 putative ESBL-producing strains to the antibiotics 
tested are shown in TABLE 3-1 and those of the 23 non-ESBL-producing strains are 
shown in TABLE 3-2. Thirty-five out o f 3 7 (95%) o f t h e ESBL-producing strains 
were resistant to 8 mg/L ceftazidime while only 13 out o f23 (57%) (95% vs. 57%, p 
< 0.01, highly significant) of the non-ESBL-producing strains were resistant. No 
ESBL-producing strains were resistant to 8 mg/L ceftazidime in the presence of 
clavulanic acid while 7 out of 23 (30%) of the ESBL-negative strains were resistant. 
In contrast, the MIC distributions of piperacillin and piperacillin + tazobactam were 
similar for the two groups of organisms: 16 - > 1024 mg/L of piperacillin for all 
organisms, and 0.5 - 64 mg/L and 2 - > 1024 ofpiperacillin + tazobactam for ESBL-
producers and non-ESBL-producers, respectively. 
The distributions of MICs of other cephalosporins were more variable. The 
MICs of cefuroxime were higher for non-ESBL-producers than for ESBL-producers 
(MIC90 > 1024 mg/L vs. MIC90 = 256 mg/L) although a similar proportion of 
isolates were resistant (95 -100%). A larger proportion of the non-ESBL-producers 
were resistant to cefoxitin (8 mg/L), cefotaxime (8 mg/L) and ceftriaxone (8 mg/L) 
(83%, 61% and 52% respectively) than the ESBL-producers (46%, 32% and 38%, 
respectively) (83% vs. 46%, p < 0.01, highly significant; 61% vs. 32%, p < 0.05, 
significant; 52% vs. 38%, p > 0.1，not significant). Although the range of MICs of 
aztreonam for the two groups were similar (0.12 - >1024 mg/L vs. 1 一 >1024 mg/L), 
more ESBL-producers were resistant to 8 mg/L aztreonam than the non-ESBL-
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TABLE 3-1 Antimicrobial susceptibilities of37 enterobacteria with ceftazidime: 
.ceftazidime + clavulanate MIC ratios > 16 
MIC (mg/L) ~ " % isolates~~~ 
A . • , . , . resistant to 
g Range MIC50 MIC90 breakpoint^ in 
bracket (mg/L) 
P-Lactams 
Ceftazidime 4 - > 1024 64 > 1024 95 (8) 
*Ceftazidime + clavulanate 0.015-4 1 2 0(8)++ 
Piperacillin 1 6 - > 1024 256 > 1024 97 (16) 
**Piperacillin + tazobactam 0.5 - 64 4 32 27(16)++ 
Cefuroxime 8 - > 1024 32 256 95 (8) 
Cefoxitin 2-512 8 256 46(8) 
Ceftriaxone 0 .06-128 4 64 38 (8) 
Cefotaxime 0.06 — 64 4 32 32 (8) 
Aztreonam 0 .12-> 1024 128 512 95 (8) 
Imipenem 0 .015 -4 0.06 0.25 0(4) 
Meropenem 0.015-0.5 0.06 0.12 0(4) 
Aminoglycosides 
Gentamicin 0.25 - 64 4 16 35 (4) 
Netilmicin 0.25 — 128 2 64 41 (8) 
Amikacin 0 . 5 - 3 2 2 16 3 (16) 
Quinolones 
Ciprofloxacin < 0.0075 - 128 0.06 64 22(1) 
Ofloxacin 0.5 - 32 0.25 64 22 (2) 
Ceftazidime + 4 mg/L clavulanic acid 
Piperacillin + tazobactam (8:1) 
十 Breakpoint concentrations according to the National Committee for Clinical Laboratory 
Standards (NCCLS, 1993a) 
^ Breakpoint concentration of ceftazidime or piperacillin only 
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TABLE 3-2: Antimicrobial susceptibilities of23 enterobacteria with ceftazidime: 
ceftazidime + clavulanate MIC ratios < 16 
MIC (mg/L) % Resistant to 
Antimicrobial Agent breakpoint+ in 
Range MIC50 MIC90 Brackets (mg/L) 
P-Lactams 
Ceftazidime 0.5 — 64 8 16 57(8) 
*Ceftazidime + clavulanate 0 .12 -64 8 32 30 (8)^ 
**Piperacillin 1 6 - > 1024 64 > 1024 87(16) 
Piperacillin + tazobactam 2 - > 1024 8 32 17(16)^ 
Cefuroxime 32 - > 1024 256 > 1024 100 (8) 
Cefoxitin 2 - 5 1 2 64 512 83 (8) 
Ceftriaxone 0.5 -512 16 128 52(8) 
Cefotaxime 2 - 2 5 6 16 64 61 (8) 
Aztreonam 1 - > 1024 8 32 48 (8) 
Imipenem 0.015-4 0.12 2 0(4) 
Meropenem 0.015 - 2 0.06 0.25 0(4) 
Aminoglycosides 
Gentamicin 0.12-32 1 16 35(4) 
Netilmicin 0.12-32 1 16 13(8) 
Amikacin 0 .5 -8 1 4 0(16) 
Quinolones 
Ciprofloxacin 0.015 -64 0.03 64 30(2) 
Ofloxacin 0.06-64 0.12 64 30(1) 
Footnote as for TABLE 3-1 
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The MIC distributions of the aminoglycosides to the ESBL-producers and non-
ESBL-producers were similar. Similar proportions of isolates of the two groups 
were resistant to gentamicin (35%) although more ESBL-producers (41% vs. 13%) 
were resistant to netilmicin. Only one isolate (an ESBL-producer) was resistant to 
amikacin. Slightly more non-ESBL-producers were resistant to ciprofloxacin and 
ofloxacin than the ESBL-producers (30% vs. 22%) but the MIC ranges were similar. 
TABLE 3-3 shows the resistance pattem of ESBL-producers and TABLE 3-4 
that of non-ESBL-prdducers. All ESBL-producers were resistant to one to 10 
antibiotics. There were 25 different resistance patterns. Most isolates were resistant 
to five antibiotics (22%) followed by those resistant to six antibiotics (19%). Equal 
proportions of isolates were resistant to seven or eight antibiotics (16%). 
CAZCXMCFXAZMPff (abbreviations as in TABLE 3-3) was the most common 
resistance pattem, being found in six isolates, followed by CAZCXMAZMPP and 
CAZCXMAZMPffNETCffOFL being found in three isolates each. The other 
patterns were found in one to two isolates each. 
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TABLE 3-3: Resistance patterns of 37 enterobacteria with 
ceftazidime: ceftazidime + calvulanic acid MIC ratios > 16 
No. of , • No. of organisms+ 
resistances esistance pa em ECOL KPNE ENTE MMOR SMAR TOTAL 
_ ^ i 0 0 0 0 1 ~ 
2 AZM PIP 1 0 0 0 0 1 
4 CAZCXMAZM PIP 0 3 0 0 0 3 
CAZ CXM CFX GEN 0 0 0 1 0 1 
5 CAZ CXM CFX AZM PIP 0 0 6 0 0 6 
CAZCXMAZM PIP NET 0 2 0 0 0 2 
6 CAZ CTR CXMAZM CTX NET 0 1 0 0 0 1 
CAZ CXM CFX AZM PIP GEN 0 0 2 0 0 2 
CAZCXMAZM PIP GENNET 0 1 0 0 0 1 
CAZ CTRCXMAZM PIP GEN 0 1 0 0 0 1 
CAZCXMAZM PIP GENNET 0 0 0 1 0 1 
CAZ CTRCXMAZM GX PIP 1 0 0 0 0 1 
7 CAZ CTR CXM CFX AZM PIP GEN 0 0 1 0 0 1 
CAZ CXMAZM PIP NET Cff OFL 0 3 0 0 0 3 
CAZ CTR CXMAZM CTX PIP NET 0 2 0 0 0 2 
8 CAZ CTR CXM CFX AZM CTX PIP NET 0 0 1 0 0 1 
CAZ CTR CXM CFX AZM CTX PIP GEN 0 0 1 0 0 1 
CAZ CXM CFX AZM PIP GEN CIP OFL 1 0 0 0 0 1 
CAZ CXMAZM PIP GEN NET CIP OFL 1 0 0 0 0 1 
CAZ CTR CXM CFX AZM CTX PIP GEN 0 0 1 0 0 1 
CAZ CTRCXMAZMCTX PIP GENNET 0 1 0 0 0 1 
9 CAZ CTR CXMAZM CTX PIP NET CIP OFL 0 1 0 0 0 1 
CAZ CTR CXM CFX AZM CTX VW GEN NET 0 0 1 0 0 1 
CAZ CTR CXM CFX AZM CTX PIP CIP OFL 0 0 0 0 1 1 
10 CAZ CTR CXM CFX AZM CTX PIP GEN CIP OFL 0 0 0 0 1 1 
TOTAL 5 15 13 2 2 37 
+ ECOL 二 Escherichia coli ； KPNE = Klebsiella pneumoniae ； KOXY 二 K. oxytoca ； ENTE = Enterobacter sp.; 
MMOR = Morganella morganii ； SMAR = Serratia marcescens. 
• CAZ = Cefatzdime; CTR = Ceftriaxone; CXM = Cefuroxime; CFX 二 cefoxitin; AZM = Aztreonam; 
CTX = Cefotaxime; PIP = Piperacillin; GEN = Gentamicin; CIP = Ciprofloxacin; OFL 二 Ofloxacin 
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TABLE 3-4: Resistance patterns of 23 enterobacteria with 
ceftazidime: ceftazidime + calvulanic acid MIC ratios < 16 
No. of . • No. of organisms+ 
resistances Resistancepattem ECOL KOXY ENTE MMORTOTAL"  
4 CAZCXMCFX PIP 1 0 1 2 4 ~ 
CTRCXM CTX PIP 1 0 0 0 1 
5 CAZCXMCFX PIP NET 1 0 0 0 1 
CAZ CXM CFX CTX PIP 0 0 0 2 2 
CTRCXMCTX PIP NET 1 0 0 0 1 
CTR CXM CFX CTX PIP 0 0 1 0 1 
CTRCXMAZM CTX PIP 1 0 0 0 1 
6 CAZ CXM CFX GEN CIP OFL 1 0 0 0 1 
CAZ CTR CXM CFX AZM CTX 0 0 1 0 1 
CXM CFX AZM GEN CIP OFL 1 0 0 0 1 
7 CAZ CTR CXMAZM CTX PIP GEN 0 1 0 0 1 
CAZ CTR CXM CFX AZM CTX PIP 0 0 1 1 2 
CXM CFX AZM PIP GEN CIP OFL 2 0 0 0 2 
CTR CXM CFX AZM CTX PIP NET 0 0 1 0 1 
8 CTRCXM CFX CTX PIP GEN CLP OFL 1 0 0 0 1 
9 CTRCXMCFXAZMCTX PIP GEN CIP OFL 1 0 0 0 1 
10 CAZ CTR CXM CFX AZM CTX PIP GEN CIP OFL 1 0 0 0 1  
TOTAL 12 1 5 5 23 
Abbreviations as in TABLE 3-3 
76 
Chapter 3 Results 
The only one isolate that was resistant to one antibiotic only (piperacillin) had 
reduced susceptibility to ceftazidime (MIC = 4 mg/L) and the MIC of ceftazidime 
was reduced significantly to 0.06 mg/L in the presence of clavulanic acid. 
Non-ESBL-producers were resistant to four to 10 antibiotics. Most isolates were 
resistant to six antibiotics (26%) followed by those resistant to five antibiotics 
(22%). CAZCXMCFXPIP was the most common resistance pattern, being found in 
four isolates while the other 16 patterns were found in one to two isolates each. 
3.3. Characterization Of p-Lactamases 
3.3.1. Isoelectric Focusing 
All isolates were shown to produce p-lactamase by the chromogenic nitrocefin 
test. The p-lactamases were then subjected to isoelectric focusing (IEF) for 
determination of their isoelectric points (pIs). A total of 29 different p-lactamases 
were detected (TABLE 3-5). Their pIs ranged from 4.7 to 9.2. Most isolates (31, 
52%) produced only one enzyme while the rest (26, 43%) produced two and three 
produced three. p-Lactamases of pI 8.2 and 7.6 were the two most common 
enzymes, being produced alone or in combination with other enzymes by 14 (25%) 
isolates each. ^-Lactamase of pI=8.6 was produced by seven isolates, three of which 
produced a second enzyme. Enzymes ofpI=7.4 were produced by six isolates, three 
of which produced another enzyme and one produced two more enzymes, and 
enzymes of pI 二 5.2 were produced by five isolates. The other p-lactamases were 
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3,3.2. £r7zyme Kinetics 
3-Lactamases from five isolates (250, 3916, 4429，4565 and 6364) were 
selected for kinetic studies. A standard strain (TEM-3) was used as a control. The 
minimal inhibitory concentrations of P-lactams for these strains are shown in 
TABLE 3-6. The putative occurrence ofESBL in M. morganii (1250 and 4429) and 
S. marcescens (4565 and 6364)，as indicated by the lowering of the MICs of 
ceftazidime to clinically susceptible levels in the presence of clavulanic acid, was 
interesting as these organisms were infrequent hosts for such enzymes. Although the 
MIC of ceftazidime to the E. coli strain (3916) was decreased only two-fold in the 
presence of clavulanic acid, it had high-level resistance to cefuroxime and exhibited 
piperacillin and tazobactam synergy and would probably produce ESBL. 
Since strain 4429 {M. morganii) gave a very weak positive reaction to nitrocefin 
(color change to red was very slow) probably because of a small amount of enzyme 
produced, kinetics of this enzyme were not determined. TABLE 3-7 summarizes the 
hydrolytic activities of the enzymes studied on seven p-lactam antibiotics and the 
concentration of inhibitor (clavulanate) required to inhibit enzymatic activity by 
50% (Iso)- The relative Vmax and relative Vmaxy^Km values were related to those for 
penicillin G, which was set at 100. All four enzymes could not hydrolyze imipenem 
and only the enzyme from M. morganii 1250 hydrolyzed aztreonam. 
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TABLE 3-6: Antibiotic Susceptibilities of theM morganii, E. coli, S. marcescens 
isolates 
MIC (mg/L) for: 
Antimicrobial Agent , ^ ^ 丄 
MMOR+ ECOL+ SMAR+ SMAR+ 
1250 3916 4565 6364 
P-Lactams 
Ceftazidime 32 16 64 512 
Ceftazidime + clavulanate * 0.06 8 1 1 
Piperacillin 16 1024 2 256 
Piperacillin + tazobactam ** 1 32 2 32 
Cefuroxime 128 >1024 128 512 
Cefoxitin 16 512 32 32 
Ceftriaxone 1 256 16 32 
Cefotaxime 4 128 16 32 
Aztreonam 4 32 128 512 
Imipenem 4 0.06 1 0.06 
Meropenem 0.12 0.03 0.06 0.5 
Aminoglycosides 
Gentamicin 8 16 8 4 
Netilmicin 1 1 2 2 
Amikacin 1 1 0.5 0.5 
！ Quinolones 
Ciprofloxacin 0.0075 64 4 4 
Ofloxacin 0.03 32 8 8 
+ Abbreviations as in TABLE 3-3 
Ceftazidime + 4 mg/L clavulanic acid 
* * 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 3 Results 
The P"lactamase from M. morganii strain number 1250 rapidly hydrolyzed 
ceftazidime; the Vmax for ceftazidime was three times faster than that for 
cefotaxime. Hydrolysis of aztreonam was slow, being similar in magnitude to that of 
ampicillin and penicillin. However, Km value for ceftazidime was about seven times 
higher than that for cefotaxime and more than 10 times higher than that for 
aztreonam. The hydrolytic efficiency of the enzyme for cefotaxime was also the 
highest as compared to the hydrolytic efficiency for other P-lactams tested. In 
contrast to these observations, the MIC of ceftazidime was eight-fold higher than 
that of cefotaxime against the strain (32 mg/L vs. 4 mg/L). The specific activity for 
cefotaxime and ceftazidime was similar but that for aztreonam was about 10 times 
lower. Clavulanic acid could efficiently inhibit the hydrolysis of cefotaxime and 
ceftazidime by the enzyme (I50 = 0.48 and 0.40，respectively). 
Cefotaxime was readily hydrolyzed by the enzyme extracted from E. coli strain 
number 3916 while hydrolysis of ceftazidime and aztreonam was very slow. This 
corresponded to the relatively low MICs of ceftazidime and aztreonam (16 mg/L and 
32 mg/L, respectively) to the isolate. However, the affmity of the enzyme to 
cefotaxime was low so that the hydrolytic efficiency was only 80% that of penicillin. 
Specific activity for cefotaxime was also low, being of the same magnitude as that 
for ampicillin. Despite of this, the MIC of cefotaxime was high (128 mg/L). 
Like the enzyme from strain number 1250, the enzyme from S. marcescens 
strain number 4565 rapidly hydrolyzed ceftazidime, the rate being four times that of 
cefotaxime，but affinity for ceftazidime was low (high Km value, 332 p,M). The 
hydrolytic efficiency of cefotaxime was highest, being eight times that of 
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ceftazidime and twice that of penicillin. Specific activity for cefotaxime was also 
high, being five times that for ceftazidime. Hydrolysis of aztreonam was not 
detectable. Similar to strain number 1250, the MIC of cefotaxime was four-fold 
lower than that of ceftazidime (16 mg/L vs. 64 mg/L, respectively) to isolate 4565. 
The substrate profile of the enzyme from S. marcescens strain number 6364 was 
similar to that of 4565 in that ceftazidime was more rapidly hydrolyzed than 
cefotaxime and aztreonam was not hydrolyzed. Affinity for ceftazidime was also 
lower than that for cefotaxime (Km = 139 vs. 9，respectively). Hydrolytic efficiency 
of cefotaxime was seven times that of ceftazidime. The MIC of cefotaxime was also 
lower than that of ceftazidime (MIC = 32 mg/L vs. 512 mg/L) to the isolate. 
The concentrations of clavulanate required to inhibit 50 % of the enzyme 
activity (I50) of the four enzymes were < 1 mM for both cefotaxime and ceftazidime 
except for enzyme 4565, when the I50 for ceftazidime was slightly > 1 mM. 
3.4. Transferability Of Resistance Plasmids 
Transferable resistances were detected in only 10 of the putative ESBL-
producers and two of the non-ESBL-producers (4566 & 5829) at frequencies 
ranging from 6.52 x 10'^ ° to 3.28 x 10"^  (TABLE 3-8). These strains were found to 
produce enzymes of pI 7.4 - 7.6. The 12 isolates were resistant to four to seven 
antibiotics including ampicillin (AMP), cefuroxime (CXM), ceftazidime (CAZ), 
ceftriaxone (CTR), cefotaxime (CTX), aztreonam (AZT) and gentamicin (GEN). 





























































































































































































































































































































































































































































































































































































































































































































































































Chapter 3 Results 
AMPCAZCXMAZM-resistance to the E. coli recipient (TABLE 3-8). 
The resistances were bome on plasmids of different sizes (122 — 218 kb) but the 
transconjugants all produced a p-lactamase of pI 7.6. Three other K. pneumoniae 
isolates (3527, 3553 & 5827) had their AMPCAZCXMAZM-, 
AMPCAZCXMAZMCTRCTX- and AMPCAZCXMAZMCTX-resistance 
transferred, the resistances being bome on plasmids of 110 kb — 128 kb and the 
transconjugants produced a p-lactamase of the same pI of 7.4 as their donors. 
Another K. pneumoniae isolate (6630) only had three of its four resistances 
transferred (AMPCAZAZM). The resistances were bome on a plasmid of 100 kb 
and both the donor and transconjugant produced a p-lactamase of pI 7.5. The only E. 
coli isolate which had its AZM-resistance transferred (5313) were resistant to AMP, 
CXM, AZM and GEN. The AMPAZMGEN-resistance was bome on a plasmid of 
96 kb and the transconjugant produced a p-lactamase of pI 8.6. The other five 
isolates (one E. coli, one K. pneumoniae, one K. oxytoca and two Enterohacter sp.) 
could only transfer the AMP-resistance although they were also resistant to CXM, 
CAZ, AZM, CTR, CTX or GEN in all or part. The AMP-resistance was usually 
bome on a large plasmid in the host strain and the transconjugants produce a p-
lactamase of the same pI as that produced by their respective hosts. 
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3.5. Molecular Studies 
3.5.1. Detection Of TEM- And SHV-Type /3-Lactamase 
Genes By PCR 
Five (29%) E. coli isolates (three non-ESBL-producers and two ESBL-
producers) produced a 1079 bp fragment after amplification using a pair of TEM-
specific primers ( la & lb in TABLE 2-6), indicating the presence of a TEM-type p_ 
lactamase gene (FIGURE 3-3)(TABLE 3-9). These isolates produced one to three p-
lactamases o f p I 5.1 - 5.8. P-Lactamases of pI 5.0 — 6.0 probably were of the TEM-
type and their presence was therefore confirmed by the detection of a TEM-type 
gene using PCR. One of the ESBL-producers which produced only one P-lactamase 
(pI = 5.1) also produced a 475 bp fragment after amplification with a pair of SHV-
specific primers (4a & 4b as in TABLE 2-6)，indicating the presence of a TEM-type 
and SHV-type p-lactamase gene (FIGURE 3-4). Another ESBL-producers 
(producing a P-lactamase of pI 8.6) produced the SHV-specific 475 bp fragment 
after PCR. 
All 15 K. pneumoniae isolates were ESBL-producers and TEM-type genes were 
present in eight (53%) of them. Four of these isolates also harbored SHV-type genes 
as detected by PCR (TABLE 3-9). Only four of these isolates produced p-lactamases 
of pI 5.0 - 6.0 indicative ofTEM-type enzymes while the other four produced one or 
more P-lactamase of pI 7.6 - 8.6. The pI of the p-lactamase Q)I = 4.7) produced by 
one of these isolates was probably too low to be a TEM-type enzyme. All the seven 
(47 %) isolates which harbored SHV-type genes produced P-lactamases of pI 7.0 -
8.0 indicative of SHV-type enzymes. 
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FIGURE 3-3: Amplification of the 1079 bp fragments by TEM-specific primers 
(la and lb). Lanes 1 and 2 contain the positive controls TEM-1 and TEM-3, 
respectively; Lane 3 contains SHV-1 as negative control; Lane 4 contains 
amplimer from E. coli; Lane 5 contains amplimer from K. pneumoniae and 
Lanes 6 to 9 contain amplimer from Enterobacter sp.; Lane M contains the DNA 
ladder (c|)x-174-RF DNA digest from Amersham Pharmacia Biotech). 
Lane 
1 2 3 4 5 6 7 8 9 M 
^^^^^^^^9^^^ S^SI^S^^^ 9^l^ !^^ S^^9l^^^?*^ i^^ S^^^^ !^^ S^^ ?^^ s^^ K^« T^rffl^  "II ^ i^^ l^ ^^ *^"sSBS 
—L 
• , . _ • • ^ ^ W 丽 W 冒 W 丽 y * " ^ ^ W ^ ' ' " ^ ™ * * ^ ! ^ 1078 bp 
l^i^ [§f(^ fl^ ^^ ^^ j^ ^^ ^^ (^j^ ^^ H^i^ ^^ j^li^ ^^ f^ij^ 2^ ^^ ^^ ^^ ^^ II^ ^^ ^^ Hg^ §^i^ ^^ l ^ ^ 
m m n ^ ^ m u u m m j m g m i ^ ^ ^ ^ ^ — sn bp 
^^^^^^^^^^^BtaBB^^m< 603 bp 
^^^K^^^m^mm 
^ ^ H ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ | ^ ^ H L ^ ^ | 
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FIGURE 3-4: Amplification of the 475 bp fragments by SHV-specific 
primers (4a and 4b). Lanes 1 to 3 contain the positive controls SHV-1, 
SHV-4 and SHV5, respectively; Lanes 4 to 7 contain TEM-1, TEM-2, 
TEM-3, TEM-5, respectively as negative controls; Lane 8 contains 
amplimer from E. coli; Lane 9 contains amplimer form K. 
pneumoniae; Lane 10 contains amplimer from Enterobacter sp. and 
Lane 11 contains amplimer from S. marcescens); Lane M contains the 
DNA ladder ((|>x-174-RF DNA digest from Amersham Pharmacia 
Biotech). 
Lane 
1 2 3 4 5 6 7 8 9 10 11 M 
^ H ^ ^ ^ ^ ^ ^ ^ ^ H ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 1353 bp 
J J U m U J H l | J I | ^ ^ ^ ^ ^ ^ ^ ^ < 4 1078 bp 
^ ^ H ^ ^ m ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 872bp 
^ H ^ E t ^ — -
^ ^ ^ ^ ^ ^ H ^ ^ ^ ^ ^ X i 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 3 Results 
TEM-type genes were only present in four of the 18 Enterobacter sp. tested 
(22%), two each of non-ESBL-producers and ESBL-producers. Only one of the non-
ESBL-producer also harbored a SHV-type gene (TABLE 3-9). Only one non-ESBL-
producer produced a p-lactamase of a pI similar to that of TEM-type enzymes (pI = 
5.5) while the other three produced p-lactamases of pI 7.4 - 8.2. In contrast, a total 
of nine (50%) (seven were ESBL-producers while two were non-ESBL-producers) 
harbored SHV-type genes. Except for one ESBL-producer which produced a p_ 
lactamase of pI 5.1, all the other SHV-type-gene-harboring isolates produced P-
lactamases o fpI 7.6 - 8.7. 
None of the seven M. morganii isolates tested produced positive PCRs for 
TEM- and SHV-type genes, indicating absence of these genes. However all these 
isolates produced p-lactamases of pI > 7.0 and one also produced an enzyme of pI 
5.0-6.0. 
Both of the two ESBL-producing S. marcescens isolates harbored SHV-type 
genes and one of these also harbored a TEM-type gene. Both isolates produced P_ 
lactamases of pI 7.0 - 8.2. 
Amplification of template DNA from control strains producing SHV-type P_ 
lactamases (SHV-1, SHV-4 and SHV-5) using the other three pairs of SHV-primers 
(2a，2b, 3a, 3b and 5a, 5b) produced PCR products other than the desired ones (800， 
292 and 649 bp, respectively). Thus they were not used for detection of Z>/asHv genes 
in the test strains. 
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3.5.2. Oligotyping For Characterization Of blajEM Genes 
Eight oligonucleotide probes (TABLE 2-7) were used to hybridize DNA of the 
60 isolates on colony blots. Hybridization signals could be obtained with these 
isolates (TABLE 3-9) using all the probes except GLY238 and SER238. 
DNA from four E. coli non-ESBL-producers and one ESBL-producer 
hybridized with one or more of the eight oligonucleotide probes, however, DNA of 
two from the non-ESBL-producers and one from the ESBL-producer did not 
produce the desired fragments after PCR using TEM-specific primers. Two non-
ESBL-producers of the five isolates hybridized with some of the probes of 
sequences specific for TEM-1 gene (GLN39 and ARG164; GLU104 and ARG164). 
These two isolates also produced p-lactamases of pI 5.0 — 6.0, indicative of enzymes 
related to TEM-1. One ESBL-producer that was positive for SHV-type gene after 
PCR hybridized with GLN39, a sequence specific also for SHV-1 gene. This isolate 
produced a p-lactamase of pI 8.6. Seven non-ESBL-producers and four ESBL-
producers did not hybridize with any of the probes. 
Of the 15 K. pneumoniae (all were ESBL-producers) tested, DNA from 10 of 
them (67%) hybridized with one or more of the probes. However, three of the 
isolates did not give a positive PCR with TEM-specific primers. Besides, they 
produced only one P-lactamase of pI 7.6. The other three isolates did not produce p_ 
lactamases o f a p I indicative of TEM-type enzymes. 
DNA from three isolates hybridized with both GLU104 and LYS104 probes and 
DNA from one of these isolates also hybridized with both GLN39 and LYS39. 
These might indicate that the isolates either produce more than one type of p-
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lactamase or that some of the hybridization signals were results of non-specific 
reactions. Five (33%) of the isolates did not hybridize with any of the probes. 
DNA of the K. oxytoca isolate (a non-ESBL-producer) hybridized with two of 
the probes specific for TEM-1 gene (GLN39 and ARG164) but it did not give a 
positive PCR result with TEM-specific primers. 
DNA from 13 (36%) (11 were ESBL-producers and two were non-ESBL-
producers) of the Enterobacter sp. tested hybridized with one or more probes but 
DNA from nine of ESBL-producers did not produce the desired fragment after PCR 
with TEM-specific primers. Besides, DNA from eight ESBL-producers and one 
non-ESBL-producers hybridized with both GLU104 and LYS104 probes. In 
addition, DNA from two non-ESBL-producers hybridized with both ARG164 and 
SER164 probes and that of a ESBL-producer hybridized with both GLN39 and 
LYS39 probes. 
Two non-ESBL-producers and one ESBL-producer of seven M morganii (43%) 
isolates tested produced hybridization signals with GLU39 or LYS39 probes. 
However, none of them were positive for TEM-type genes after PCR with TEM-
specific primers. 
One of the two S. marcescens isolates produced hybridization signals with 
GLN39 and ARG164 probes. This isolate was positive for PCR using SHV primers, 
indicating presence of SHV-l-like gene. 
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3.5.3. ^Lactamase Types Inferred From Results OfPCR 
And Oligotyping 
Eight of the 15 (53%) K. pneumoniae isolates produced TEM-type p-lactamases 
(one of these enzymes being TEM-l-like), four of which also produced SHV-type 
enzymes. Three other isolates produced SHV-type enzymes only. The remaining 
four (27%) isolates produced p-lactamases that were not TEM- or SHV-type. The 
only K. oxytoca isolate in this study produced a P-lactamase not of the TEM- and 
SHV-type. 
About two-thirds of the ESBL-producing Enterobacter sp. produced p-
lactamases of either TEM- or SHV-type. Most of these isolates (54%) produced 
SHV-type enzymes, four of which were SHV-l-like. Two isolates produced TEM-
type enzymes only and the rest (four isolates) produced enzymes that were not 
TEM- or SHV-type. 
Only five Enterobacter sp. were non-ESBL-producers. Two produced SHV-
type enzymes, one of which also produced a TEM-l-like enzyme and the one other 
isolate produced a TEM-type enzyme only. 
3-Lactamases produced by all the seven M. morganii isolates studied were non-
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3.5.4. Characterization OfblasHv Genes Using 
Polymerase Chain Reaction-Single Strand 
Conformational Polymorphism (PCR-SSCP) 
The two S. marcescens (4565 and 6364) isolates that produced a P-lactamase of 
pI 8.2 and were positive for SHV-type p-lactamase genes after PCR using SHV-
specific primers were subjected to PCR-SSCP analysis. Three SHV-type p-
lactamase-producing strains (SHV-1, SHV-4 and SHV-5) were used as positive 
controls and TEM-1 as negative controls. Both these two isolates showed a PCR-
SSCP pattem indistinguishable from that of SHV-5-producing strain, thus probably 
harboring a SHV-5 encoding gene (FIGURE 3-5). 
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FIGURE 3-5: PCR-SSCP analysis of test and standard strains producing SHV-
type P"lactamases. Lanes 1 and 2 contain the test strains 6364 and 4565, 
respectively; Lanes 3 to 5 contain the standard strains producing SHV-5, SHV-4 
and SHV-1, respectively. DNA from the negative control (TEM-1) did not 
produce any amplimer after amplification using the SHV-specific primers (result 
not shown). 
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Discussion 
4.1. Antimicrobial Susceptibilities Of ESBL- Vs. Non-ESBL-
Producers 
Significantly, more putative ESBL-producers were resistant to ceftazidime and 
aztreonam (95%) than non-ESBL-producers (57% and 48%, respectively)Oo < 
0.001). In contrast, more non-ESBL-producers were resistant to cefotaxime, 
ceftriaxone and cefoxitin (61%, 52% and 83%, respectively) than ESBL-producers 
(32%，38% and 46%, respectively) (61% vs. 32%, p < 0.05, significant; 52% vs. 
38%,p>0.1 , not significant; 83% vs. 46%,p<0.01, highly significant). For non-P-
lactam antibiotics, only netilmicin seemed to be more active against non-ESBL 
producers. Whether such differences of apparently high-levels ofresistance to the p_ 
lactams were clinically significant enough to treat the two groups of organisms 
separately when considering antibiotic choice is questionable. It could be assumed 
that strains that were resistant to ceftazidime or if they were sensitive to ceftazidime 
but the ceftazidime: ceftazidime + clavulanic acid MIC ratios were <16 would be 
more likely to be resistant to most other cephalosporins and such drugs should not 
be used on patients infected by these organisms. 
All the isolates, regardless of whether they produced ESBL or not, were 
resistant to up to 10 antibiotics tested. Thus, multiple resistance was prevalent 
amongst these isolates. Cross-resistance not only to p-lactams but to other classes of 
antibiotics such as aminoglycosides and quinolones existed not uncommonly. 
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Clinicians would be faced with severe therapeutic problems when such infections 
were encountered. 
4.2. Transferability Of Resistances 
It was surprising to find that only 27% of the ESBL-producers could transfer 
their P-lactam resistances and the transfer frequencies were very low (6.52 x 10"^ ^ — 
3.28 X lQ-6). These transferable resistances were usually bome on large plasmids of 
size 50 - 218 kb. The non-transferable resistances were either bome on non-
transferable plasmids or were on the chromosome. This finding could probably 
explain why the prevalence of ESBL-producers in Hong Kong had not increased as 
rapidly as would have been if most of the resistances were bome on transferable 
genetic elements. Similarly, only two of the 23 non-ESBL-producers could transfer 
their resistances. 
4.3. Mechanisms Of Resistance To Extended*^pectrum 
Cephalosporins 
All 60 enterobacterial isolates selected for study showed a positive disk 
diffusion synergy test, i.e. cefotaxime, ceftriaxone, ceftazidime or aztreonam were 
synergistic with clavulanate in inhibiting the growth of these organisms. However, 
when the MICs of these P-lactams and those of ceftazidime in the presence of 
clavulanic acid were determined, it was found that only 37 (62%) gave ceftazidime: 
ceftazidime + clavulanate MIC ratios > 16. ESBL-producers were defined as those 
that gave ratios > 16. These putative isolates were K. pneumoniae (15 o f l 5 ) , E. coli 
(five of 17)，Enterobacter sp, (13 of 18)，M. morganii (two of seven) and S. 
marcescens (two oftwo). The 23 isolates gave ratios one to eight and were resistant 
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to one or more of the extended-spectrum cephalosporins and aztreonam. p_ 
Lactamases produced by all these isolates were therefore investigated. 
As with findings from other parts of the world, ESBLs were usually produced 
by Klebsiella sp. All of the 15 K. pneumoniae isolates in this study were putative 
ESBL-producers. Only 29% of the E. coli isolates were putative ESBL-producers. 
This fmding was also in line with reports from other regions that ESBL-production 
by E. coli was not as common as that by Klebsiella sp. 
What was more interesting in this study was the high proportion of 
Enterobacter sp. (72%) that were putative ESBL-producers. The findings of two 
isolates, each of M morganii and S. marcescens that produced ESBL were also 
interesting. These organisms were infrequent hosts ofESBL and the identity ofthese 
ESBLs would be most interesting. Due to limitation of time, only five isolates were 
selected for detailed kinetic studies of the enzymes produced. These were the two 
isolates of M. morganii and S. marcescens, and the E. coli isolate that was highly 
resistant to cefuroxime (MIC > 1024 mg/L) in addition to being resistant to 
cefotaxime, ceftriaxone, ceftazidime and aztreonam and resistance to piperacillin 
was reduced 32-fold in the presence of tazobactam despite ceftazidime MIC being 
reduced only two-fold in the presence of clavulanic acid. Since enzyme extraction 
from one of the M. morganii isolate was not sufficient for kinetic studies (even from 
6-L culture), the kinetic studies were performed on p-lactamases from only four 
isolates. 
Approximately similar numbers of K. pneumoniae produced TEM- and SHV-
type ESBLs, eight and seven, respectively. Four of these isolates produced both 
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TEM- and SHV-type ESBLs. The enzymes from three of the isolates were non-
TEM- and non-SHV-type. These results were also quite different from findings from 
other parts of the world. Piddock and colleagues (1997) found that in a survey of 
ESBL-producers in the United Kingdom, all their Klebsiella sp. produced either 
SHV-type, non-TEM- or non-SHV-type enzymes. Prevalence of Klebsiella sp. 
producing SHV-type enzymes was also found in Korea (Kim et al,, 1998) and Greek 
hospitals (Tzouvelekis et al, 1998). Whether the strains isolated in this study were 
different from those of others causing them to be more prone to acquire TEM-type 
(^-lactamase gene has to be determined by further studies such as molecular typing 
and mutagenesis studies. 
Ofthe five putative ESBL-producing E. coli isolates, three produced TEM-type 
and/or SHV-type enzymes. TEM-type enzymes were also produced by non-ESBL-
producers. However, resistance to extended-spectrum cephalosporins of these 
isolates was probably mainly due to enzymes not ofthe TEM- or SHV-type. 
Aboul 70 % of lhc 13 putative ESBL-producing Enterohacter sp. produced 
rEM-or SHV-type enzymes, the laller being the major types of enzymes produced. 
It would bc inleresling lo study in detail the ESBLs produced by these organisms 
aiul thc nicchanisms that pcrlain thcir bcing a regular host of ESBL, such as thc 
slabilily of ESBL gencs within them. Similar proportions of non-ESBL producers 
were rcsisiant to thc |i-lactams due lo cither TEM- or SfiV-lypc enzymcs or 
cnzynics not ofthcsc types. 
All M. niorganii isolates produccd en/ymes that were not TEM- or SHV-type, 
regardless ofwhcther the enzymes were ESBLs. In contrast, both lhc S. marcescens 
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produced ESBLs of SHV-type. Results of biochemical and molecular studies 
showed that the enzyme was SHV-5, originally isolated from a K. pneumoniae 
isolate (Gutmann et al., 1989). The origin of this en2yme could be located by 
studying in detail SHV-type enzymes produced by K. pneumoniae isolate in this 
locality. Selection ofsuch enzyme could also be investigated by growing sensitive S. 
marcescens in the presence of extended-spectrum cephalosporins and ESBL-
producing K. pneumoniae. 
In sununary, the predominant ESBLs in this study were SHV-type and they 
were usually produced by K. pneumoniae and Enterohacter sp. ESBL production 
was not common in E. coli while rare hosts of ESBLs such as M. morganii and S. 
marcescens had the potential to become important ESBL-producers. 
4.4. Kinetic Studies Of p-Lactamases From E. coli (3916), M. 
morganii (1250) And S. marcBScens (4565 & 6364) 
Although the MIC of ceftazidime was reduced only by two-fold in the presence 
of clavulanic acid against E. coli (3916), the resistance mechanism of this isolate 
was very interesting. Firstly, this isolate was resistant to the extended-spectrum 
cephalosporins tested including cefotaxime, ceftriaxone and ceftazidime and 
aztreonam. Secondly，it had very high cefuroxime MIC (MIC > 1024 mg/L). Over-
production of chromosomal P-lactamases alone could not explain this phenomenon. 
Thirdly, there was synergy between piperacillin and tazobactam against this isolate. 
This synergistic effect was similar to that observed for TEM-60 (Franceschini et aL, 
1998). All these pointed towards presence of a novel p-lactamase. The isolate 
produced an enzyme of pI 7.6 suggestive of an SHV-type enzyme. Substrate profile 
of the enzyme was similar to that of SHV-7 in that cefotaxime was hydrolyzed much 
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faster than ceftazidime although the isolate was resistant to both cephalosporins. 
Ceftazidime hydrolysis was so slow that it could not be detected in this study. Km 
therefore could not be determined. Presumably mechanisms other than production of 
P-lactamase were responsible for resistance to ceftazidime in this isolate. 
Amplification o fDNA from this isolate with SHV- or TEM-specific primers did not 
produce a positive reaction，indicating that the enzyme was not SHV- or TEM-type. 
Further work on cloning and sequencing of the p-lactamase gene would be required 
to confirm its identity. 
Presence of ESBL in M. morganii was an interesting phenomenon as the 
organism was a rare host ofESBL (Bush et al., 1995; Sirot, 1995; Bush & Jacoby, 
1997). M. morganii 1250 produced an enzyme of pI 7.5 suggestive of SHV-type 
enzyme but resistances conferred were similar to those conferred by TEM-7. 
Ceftazidime was hydrolyzed three times faster than cefotaxime, however, because of 
the low affinity of the enzyme for ceftazidime, Vmax/Km was highest for 
cefotaxime. Despite of efficient hydrolysis of cefotaxime by the enzyme, the isolate 
remained susceptible to this drug (MIC 二 4 mg/L). This phenomenon was similar to 
that observed for TEM-E2. However, as for E. coli 3916，results o fPCR with TEM-
and SHV-specific primers were negative, indicating that the enzyme was not derived 
from TEM- or SHV-type p-lactamases. The enzyme therefore was probably also a 
novel one but further work had to be done to confirm this hypothesis. 
ESBLs were produced by the two S. marcescens isolates (4565 and 6364), 
another rare host for ESBL. Recently, an outbreak of S. marcescens that produced 
both TEM-type and SHV-type ESBLs was reported in Italy (Luzzaro et al., 1998). 
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This indicated that ESBL-producing S. marcescens could become a serious problem. 
These enzymes had similar substrate profiles and specific activities were of similar 
magnitude. Hydrolytic efficiencies for all the p-lactams of the 6364 enzyme were 
much higher that those ofthe 4565 enzyme, explaining the much higher MICs (MIC 
ofceftazidime: 512 mg/L and 64 mg/L, respectively). Although both enzymes could 
not efficiently hydrolyze aztreonam, the isolates were resistant to aztreonam in 
addition to ceftazidime and had reduced susceptibility to cefotaxime. This resistance 
profile together with a pI of 8.2 was similar to SHV-5. Amplification of template 
DNA with SHV-specific primers produced the desired fragment and PCR-SSCP 
analysis ofthe amplimer indicated the presence of an SHV-5 gene. 
The enzyme produced by these two isolates were therefore confirmed to be 
SHV-5. They probably had acquired the p-lactamase gene from K. pneumoniae 
strains. This hypothesis could be tested by analyzing SHV-type amplimers from K. 
pneumoniae isolates producing enzymes of pI 8.2 using the method of PCR-SSCP 
and then identifying the location of the gene. If the gene was located on a plasmid, 
experiments could be carried out to determine if the plasmid was transferable and if 
it could be stable within the S. marcescens host. 
4.5. Methods For The Detection of ESBLs 
One of the methods used for the detection of ESBL production was the double 
disk synergy test (Jarlier et al” 1988). In this test, an amoxicillin/clavulanate disk 
was placed in the center of an agar plate with a lawn of the test strain and 
cefotaxime, ceftriaxone, aztreonam and ceftazidime disk were placed 30 mm away 
from the amoxicillinMavulanate disk and from each other. An extension of the zone 
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of inhibition of either the cefotaxime, ceftriaxone, aztreonam or ceftazidime disk 
towards the amoxicillirL^clavulanate disk (an indication of synergy) together with 
decreased susceptibility to these four p-lactams would indicate presence of ESBL. 
This method was claimed to be sensitive in detecting ESBL-producing organisms. 
However, care must be taken to ensure the potency of the clavulanate component in 
the amoxicilliny^clavulanate disk. Loss of potency of clavulanic acid during storage 
may give rise to false-negative results (Moland & Thomson, 1994). Besides, some 
ESBLs were not efficiently inhibited by clavulanic acid. For strains producing these 
enzymes, disk spacings smaller than 30 mm had to be used to increase the sensitivity 
of the test. In addition, the method will not be sensitive in detecting ESBLs if 
another p-lactamase is also produced by the strains (Moland & Thomson, 1994). p_ 
Lactamases that have extended-spectrum of activity but not inhibited by clavulanic 
acid could not be detected (Thomson et al” 1991; Thomson & Sanders, 1992). 
Another method for the detection of ESBL was determination of the minimal 
inhibitory concentrations (MICs) of the p-lactams alone and in combination with 
clavulanic acid. A decrease by several folds of the MICs of extended-spectrum 
cephalosporins in the presence of clavulanic acid would indicate the presence of 
ESBL. Livermore & Yuan (1996) found that ceftazidime: ceftazidime + clavulanic 
acid MIC ratios > 16 were indicative ofESBL production. 
In this study, 60 enterobacterial strains that had a positive double disk synergy 
test were studied for the production of ESBL. All of the 60 strains had shown 
synergy (enhancement of the zone of inhibition) between the centered 
amoxicilliny^clavulanate disk and the newer cephalosporins disks at the periphery. 
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However, determination of the MICs of ceftazidime alone and in the presence of 
clavulanic acid and subsequent calculation of the ceftazidime: ceftazidime + 
clawlanate MIC ratios showed that the ratios varied greatly from one to 2133. A 
bimodal distribution was found with peaks at MIC ratios of one and 128. However, 
since all the isolates were resistant to one or more of the extended-spectrum 
cephalosporins and /or aztreonam, they were presumed to produce ESBLs that might 
or might not be inhibited by clavulanic acid. 
Those isolates which showed ceftazidime: ceftazidime + clavulanate MIC ratios 
> 16 would be referred to as ESBL-producers (belonging to Group 2be of Bush's 
functional scheme (Bush et al., 1995)) and those which showed ratios < 16 referred 
to non-ESBL-producers in the strictest sense. p-Lactamases produced by the latter 
group of organisms probably would belong to Group 2br ("broad-spectrum P-
lactamase with reduced binding of clavulanic acid") of ihe same scheme (Bush et 
al., 1995). 
By comparing results of the two methods in this study, it seemed that the disk 
difflision synergy test would only be a preliminary detection method for ESBL while 
definitive identification would depend on the determination of MICs. Since some 
ESBLs conferred resistance to P-lactams other than the extended-spectrum 
cephalosporins, e.g. TEM-22 conferred resistance to aztreonam but not the other 
cephalosporins (Arlet et al, 1993), MICs of aztreonam alone and in combination 
with clavulanic acid should also be determined. In this study, there was one isolate 
that produced an enzyme which was inhibited by tazobactam but not clavulanic acid 
(strain number 3916, E. coli, ceftazidime: ceftazidime + clavulanate MIC ratio 二 2, 
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piperacillin: piperacillin + tazobactam MIC ratio 二 32). As more new ESBLs are 
evolved, it appeared that activity of cephalosporins other than ceftazidime in 
combination with a P-lactamase inhibitor would have to be studied. 
4.6. Methods For The Identification Of p-Lactamases 
Isoelectric focusing has been used since the 1970s for determination of the 
isoelectric points ^)Is) of p-lactamases which were then found to be different for 
each enzymes. Thus, IEF remained the mainstay for identification of p-lactamases. 
The method has been simplified recently and became increasing popular as ready-
made gradient gels were available commercially. However, there were innate 
problems with the method. IEF of enzymes often revealed multiple "satellite bands". 
These bands were actually the monomeric and dimeric forms of the enzyme 
molecule that arose due to loss or modification of amino acid residues (Simpson & 
Plested, 1983). Such changes led to molecules with different net charges resulting in 
bands focusing at different pIs. The intensity of satellite bands for a given p_ 
lactamase might vary according to the host strain or even the culture of the strain 
(Labia et aL, 1976; Simpson et al., 1982). Sometimes it would be difficult to decide 
which band should be taken as the major one of the enzyme, thereby giving 
erroneous data on the pL Experience on the part of the worker is most important. 
Otherwise, the experiment should be repeated several times and the band, which 
always appeared first after treatment with nitrocefin would be the major band. 
The pIs of some p-lactamases varied only minimally e.g. TEM-1 has a pI of5.4 
(Bush et al., 1995) and TEM-7 has a pI of5.41 (Gutmann et al., 1988); TEM-10 has 
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a pI of 5.57 and TEM-26 has a pI of 5.58 (Bush et al, 1995). It would be extremely 
difficult to determine exactly the pIs of these enzymes. 
As more enzymes were discovered, it was found that different P-lactamases 
might have identical pI values (Bush et al., 1995). A p-lactamase of pI 7.6 may 
probably be SHV-1, SHV-2 or SHV-6, while that of 8.2 may be SHV-5, P99 or 
FEC-1. In this study, we found that some p-lactamases o fp I 7.6 were not SHV-type 
as DNA from strains producing these enzymes did not give a positive PCR with 
SHV-specific primers. Thus, we could not use pI as the sole means of identification 
of a p-lactamase. 
Investigation ofthe kinetic parameters of a P-lactamase would be a much better 
and discriminatory method for identification. This is because different P-lactamases 
varied in their hydrolysis and affinity of different substrates and in the extent of 
inhibition by different inhibitors. The enzyme kinetics could be followed 
spectrophotometrically and the rate of hydrolysis determined (Samuni, 1975; Bush 
& Sykes, 1986). However, there are several drawbacks. Firstly, pure enzymes had to 
be used. Several litres of bacterial cultures had to be prepared before sufficient 
amount of enzymes to be purified by ammonium sulphate treatment and column 
chromatography was available for kinetic studies. The process was a long and 
tedious one. If more than one P-lactamase were produced by the organism, each 
enzyme had to be separated by preparative IEF. The spectrophotometric assay itself 
was also a tedious and time-consuming procedure. One could not afford to 
determine the kinetic parameters of each enzyme for identification except if results 
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of other investigations were suggestive of a novel enzyme. Hydrolysis data should 
be presented in the ratio Vmax/Km (efficiency of hydrolysis) for comparison 
purposes since the ratio reflected the resultant effect of hydrolytic and binding 
activities. This is especially important if inter-laboratory data were to be compared, 
as different laboratories would have different conditions in performing the 
experiments. 
Amplification ofDNA ofthe strain producing P-lactamases using P-lactamase-
specific primers by PCR could be used to detect the presence of p-lactamase genes. 
In 
this study, one pair ofTEM-specific primers and four pairs of SHV-specific primers 
(TABLE 2-6) were used. It was found that only one pair of SHV-specific primers 
which gave an amplimer of450 bp was "specific" in detecting the presence of SHV-
type genes. The other three pairs of primers were either not specific or produced 
amplimers of sizes other than the desired ones. This was probably due to conditions 
ofthe PCR, especially the annealing temperature and the metallic ion concentration. 
The PCR method was simple, quick and reliable and could be used for screening for 
P-lactamase genes provided that the primers selected were specific and conditions 
for PCR had been optimized. All possible contaminations should be avoided as for 
other PCRs and both positive and negative controls should always be included in 
eachbatch ofPCR. 
Hybridization with oligonucleotide probes was also used to detect mutated 
TEM-type genes in this study. This method, known as "oligotyping", used 
oligonucleotides synthesized according to the mutated sequences as probes to 
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hybridize with DNA ofstrains suspected to produce TEM-type enzymes (Mabilat & 
Courvalin, 1990). Theoretically, this was a good method as most of the sequences of 
ESBL genes had been sequenced and those sequences that differed from TEM-1 and 
from other TEM-type genes were known. However, the method had the innate 
disadvantages of being tedious, time-consuming and producing false-positive 
signals. We found that some strains hybridized with both GLU104 and LYS104 
probes and some with both ARG164 and SER164 probes. This was possible only if 
the strain produced two enzymes, one with an amino acid substitution ofGLU at 104 
(numbering according to Ambler et al., 1991) and another with substitution ofLYS, 
and the other strain produced an enzyme with an amino acid substitution o fARG at 
164 and a second enzyme with substitution of SER, respectively. Another 
explanation would be that either one or both of the signals were non-specific. There 
were also strains that hybridized with some of the probes but were negative for PCR 
with TEM-specific primers. These again were most probably false-positive 
hybridization signals. 
Novel ESBLs continued to evolve and probably it would be difficult to keep up 
with the number ofprobes that need to be used. However, oligotyping still remained 
to be a good screening method for existing ESBL genes. The original paper of 
Mabilat and Courvalin (1990) on oligotyping described the use of colony blots for 
hybridization. In view ofthe.large numbers ofnon-specific results, probably due to 
non-specific reactions with cell debris or culture medium constituents, it would be 
better if Southern blot be used as only extracted DNA would be involved in the 
hybridization process. 
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PCR-SSCP was originally developed to detect mutation in human genes (Orita 
et aL, 1989) but it was recently applied for the detection of mutated SHV-type genes 
(M' Zali et al., 1996 & 1998). We used this method to determine the identity of the 
ESBL produced by two S. marcescens isolates in this study and found it to be rapid 
and reliable. The availability of a commercially-available precast polyacrylamide gel 
suitable for separation of DNA made the method more user-friendly. Known SHV-
type genes must be included in each run for comparison purposes. If a PCR-SSCP 
pattem did not match with any of that ofknown genes, a novel gene sequence might 
be involved. Ultimately the gene had to be sequenced to locate the site(s) of 
mutation. 
SHV-type ESBLs, especially SHV-4 and SHV-5 seemed to be the most 
common ones in recent surveys conducted in other parts of the world (Jacoby & 
Han, 1996; Yuan et al, 1997)� 
4.7. Major Contributions Of This Study 
In this study, ESBLs produced by clinical enterobacterial isolates collected in 
1996 in The Prince of Wales Hospital were characterized. We found that out of 163 
ceflazidime-resistant isolates, only 60 showed synergy between ceftazidime and 
clavulanate using the double-disk diffusion test. This indicated that not all 
ceftazidime-resistance was due to ESBLs and the identification of ESBL-producers 
had to be carried out by more refined techniques. Considerably large proportion of 
these enterobacterial isolates produced SHV-type ESBLs. This is in contrast with 
situations in other parts of the world where TEM-type ESBLs predominated. 
Besides, most ESBL-producers were resistant to multiple antibiotics. Thus, choice 
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of antibiotics for treatment of infections caused by such organisms would be very 
much limited. 
Different enterobacterial species were found to produce ESBLs. These included 
the usual ESBL-producer K. pneumoniae as well as less common ones such as E. 
coli and Enterohacter sp. The prevalence of Enterobacter sp. producing ESBLs was 
probably unique in this region. This probably reflected the type of antibiotic 
regimens commonly used that nutured the development ofsuch strains. 
Some organisms such as S, marcescens and M. morganii which were regarded 
as infrequent ESBL-producers in the past were found to produce ESBL in this study. 
This indicated that continuous surveillance ofESBL-producers should be carried out 
and that infection control measures should be strictly adhered to in order to prevent 
spread of such resistant organisms. 
4.8. Areas For Future Research 
This study had led to various opportunities for future work to be done. 
1. Plasmid profile analysis could be done on all the isolates tested. This could 
reveal whether there was some endemic plasmids circulating within the bacterial 
population and serving as vehicles of resistance genes or that acquisition of 
resistance genes was chance occurrence. Although only a small proportion ofthe 
P-lactamase genes were bome on transferable plasmids, other forms of genetic 
exchange might aid in the spreading ofthese genes as long as they were bome on 
extrachromosomal elements. 
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2. As more new enzymes evolved due to one or more new mutations to existing p_ 
lactamase genes, the list of probes designed to reveal these mutated sequences 
and used in hybridization studies would also continue to become longer. Perhaps 
an array of probes similar as those of DNA chips recently investigated for 
identification of genes associated with human disease (Constantine & 
Harrington, 1998) could be developed for rapid identification of ESBL genes. 
Therapeutic regimens could be guided by such results and measures could be 
taken to prevent the spread of the resistance genes as soon as they were detected. 
3. PCR-SSCP was an accurate and rapid method for the detection ofmutated genes. 
This method has now been developed for SHV-type genes. Work should be done 
to develop this method for the detection of mutated TEM-type genes since these 
genes were quite prevalent amongst our isolates as shown by results of this 
study. 
4. The presumptive novel p-lactamases produced by the E. coli (3916) and M. 
morganii (1250) isolate could be further studied to confirm their identity. The 
encoding genes could be cloned and sequenced and the genes could be used to 
transform a standard E. coli strain to express the p-lactamases. The kinetics of 
the P-lactamases and the resistance profile of the transformed strains could be 
studied and compared with those from the parent strains. This could reveal 
whether P-lactamases within different hosts would affect the level of resistances 
conferred. 
115 
Chapter 4 Discussion 
5. It is still very intriguing why p-lactam use could trigger the development of 
mutated P-lactamase genes. Preliminary studies in this laboratory had shown that 
resistance to p-lactams could develop in the presence of p-lactams but different 
P-lactams had different potentials to induce or select resistance (Chan et al., 
1998). Similar work could be done on non-ESBL-producers to reveal the 
mechanisms of development of resistance to extended-spectrum cephalosporins. 
6. Attempts should be made to determine whether the ESBL-producers were 
similar or different by typing the organisms using molecular techniques. This 
could reveal the epidemiology of the resistant strains. The epidemiology of 
Enterohacter sp. in this study would be most interesting because of the relatively 
large numbers that produce ESBLs. If they were all sporadic strains, this could 
indicate that they were potential hosts for ESBLs and strict measures should be 
taken to prevent their spread. 
As most enterobacters produce class C chromosomal enzymes that were 
inducible, they were resistant to almost all penicillins and cephalosporins. With 
the development of ESBL genes in these organisms, they could ultimately 
become resistant to all penicillins and cephalosporins and spread of such 
organisms within the patient population would mean that antibiotic choice would 
be very much limited. 
7. Continuous surveillance of ESBL-producing clinical isolates should be 
performed. Hopefully, the seriousness of ESBLs in compromising therapeutic 
regimens could arouse the awareness of health care professionals in aiding to 
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reduce the prevalence of such organisms such as by more pmdent use of 
antibiotics and effective means of infection control. 
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